Compositions and methods for generation of bovine pluripotent embryonic stem cells
The use of a specific composition with inhibitors and growth factors in the cell culture medium addresses the challenges of generating bovine pluripotent stem cells by maintaining pluripotency and self-renewal, enabling successful long-term culture and differentiation.
Patent Information
- Application Number
- PCT/US2024/030927
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-24
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for generating bovine pluripotent stem cells face challenges such as irregular colony morphology, limited pluripotent gene expression, failure in long-term culture, and lack of in vivo differentiation and chimeric animal testing, with no direct germline contribution and in vitro PGC induction reported for bovine stem cells.
A composition comprising a cell culture medium supplemented with a Wingless/Integrated inhibitor, histone methyltransferase DOT1L inhibitor, adenyl cyclase activator, MEK1/2 inhibitor, fibroblast growth factor receptor inhibitor, glycogen synthase kinase 3 inhibitor, and leukemia inhibitory factor, along with bovine serum albumin, basic fibroblast growth factor, and transforming growth factor β1, which maintains pluripotency and self-renewal capacity of bovine pluripotent stem cells.
The solution effectively maintains pluripotency and self-renewal capacity of bovine pluripotent stem cells, enabling long-term culture, in vitro differentiation, and successful chimeric animal testing, including direct germline contribution and PGC induction, thereby overcoming previous limitations in bovine stem cell generation.
Smart Images

Figure US2024030927_28112024_PF_FP_ABST
Abstract
Description
COMPOSITIONS AND METHODS FOR GENERATION OF BOVINE PLURIPOTENT EMBRYONIC STEM CELLSRELATED APPLICATION INFORMATION
[0001] This application claims priority to U.S. Patent Application No. 63 / 468,697, filed on May 24, 2023, the contents of which are herein incorporated by reference.GOVERNMENT SUPPORT
[0002] This invention was made with government support under 58-8042-0-028 awarded by the Agricultural Research Service, and 2019-67015-29413 awarded by the National Institute of Food and Agriculture. The government has certain rights in the invention.SEQUENCE LISTING STATEMENT
[0003] The contents of the electronic sequence listing titled UCONN-43084-601.xml (Size: 13,431 bytes; and Date of Creation: May 20, 2024) is herein incorporated by reference in its entirety.FIELD OF THE DISCLOSURE
[0004] Described herein are bovine pluripotent embryonic stem cells, the composition (also called as TiF2 and TiF3 medium), and methods for the generation of the bovine pluripotent stem cells, the unique medium allows bovine pluripotent stem cells to maintain their pluripotent and self-renewal properties, and uses thereof. More particularly, the invention relates to the generation of bovine pluripotent stem cells from bovine pre-implantation embryos produced in vitro or in vivo.BACKGROUND
[0005] The studies and applications of embryonic stem cells (ESCs), derived from the inner cell mass (ICM) of the blastocysts, have advanced dramatically since their first establishment in mice and humans. Due to their origins, unlimited self-renewing capacity and pluripotentdifferentiation potentials, ESCs can be used to determine the mechanisms of pluripotency maintenance, create disease models for causation investigation and drug screening, understand early embryogenesis, differentiation and development, and create interspecies chimeras for research and potential xenotransplantation applications. As the economically most important domesticated ungulates, bovine provides up to 45% of the global animal protein supply. Generating ESCs from the bovine would not only contribute to the development of new agricultural biotechnology such as cultivated meat, improved production efficiency, quality and safety of animal products, disease-resistance through molecular breeding and genome editing, but also permit the development of stem cell- and animal-based models to study the pathogenesis and treatment to important zoonotic diseases such as bovine spongiform encephalopathy, bovine tuberculosis, and Toxoplasma gondii infection. The bovine ESCs are also good biomedical models for human regenerative medicine and tissue / organ replacement therapy.
[0006] While much effort has been devoted to deriving bovine ESCs (bESCs), most of the cells showed irregular colony morphology, limited pluripotent genes expression, failure in long- term culture, and lack of in vivo differentiation and chimeric animal testing. The primed-state bESCs also exhibited undefined colony morphology and lacked chimeric capacity determination, while bovine expanded potential stem cells (bEPSCs) only showed low efficiency and minor contribution in interspecies chimera with mice. Furthermore, no direct germline contribution and in vitro PGC induction has been reported for any reported bovine stem cells. Therefore, reliable methods to generate bESCs and the bona fide bESCs are highly desired.SUMMARY
[0007] In one embodiment, the present disclosure relates to a composition to grow a cell line. In some embodiments, the composition comprises:
[0008] i. a cell culture medium; and
[0009] ii. a supplement comprising:
[0010] a) a Wingless / Integrated (WNT) inhibitor;
[0011] b) a histone methyltransferase DOT1L inhibitor (iDOT1L);
[0012] c) an adenyl cyclase activator;
[0013] d) a Mitogen-activated protein kinase kinases 1 and 2 (MEK1 / 2) inhibitor;
[0014] e) a fibroblast growth factor receptor (FGFR) inhibitor;
[0015] f) a glycogen synthase kinase (GSK-3) inhibitor; and
[0016] g) a leukemia inhibitory factor (LIF),
[0017] wherein the composition maintains pluripotency and self-renew capacity of the cell line.
[0018] In some embodiments, the supplement further comprises: bovine serum albumin (BSA); a basic fibroblast growth factor (bFGF); and a transforming growth factor β1 (TGF β1).
[0019] In some embodiments, the culture medium used in the composition is a serum free culture medium for culturing stem cell lines. In other embodiments, the culture medium used in the composition is mTeSR-plus or N2B27.
[0020] In some embodiments, when the culture medium is N2B27, the supplement further comprises:
[0021] bovine serum albumin (BSA); a basic fibroblast growth factor (bFGF); and a transforming growth factor β1 (TGF β1).
[0022] In still other embodiments, the composition comprises at least 99% of the cell culture medium and about 1% of the supplement.
[0023] In yet still other embodiments, the supplement in the composition comprises:
[0024] a) from about 0.1 μM to about 25 pM of the WNT inhibitor;
[0025] b) from about 0.1 pM to about 25 pM of the histone methyltransferase DOT1L inhibitor;
[0026] c) from about 0.1 pM to about 10 pM of the MEK1 / 2 inhibitor;
[0027] d) about 0.1 pM to about 10 pM of the FGFR inhibitor;
[0028] e) from about 0.5 pM to about 10 pM of the GSK-3 inhibitor;
[0029] f) from about 1 pM to about 50 pM of the adenyl cyclase activator; and
[0030] g) about 100 U / ml to about 5000 U / ml of LIF.
[0031] In some embodiments, when the supplement also comprises BSA, bFGF, and TGF β1, the supplement in the composition comprises: from about 0.01 to about 5% (v / v) of BSA; from about 10 to about 500 ng / ml of bFGF; and from about 0.1 to about 5 ng / ml of TGF β1.
[0032] In still further aspects, in the supplement:
[0033] a) the WNT inhibitor is IWR1 ;
[0034] b) the histone methyltransferase DOT1L inhibitor is EPZ004777;
[0035] c) the adenyl cyclase activator is forskolin;
[0036] d) the MEK1 / 2 inhibitor is PD184352;
[0037] c) the FGFR inhibitor is SU5402;
[0038] f) the GSK-3 inhibitor is CHIR99021; and
[0039] g) the FIF is a human LIF or a bovine LIF.
[0040] In some embodiments, when the supplement also comprises BSA, bFGF, and TGF β1: the bFGF is a human bFGF or a bovine bFGF; and the TGF β1 is a human TGF β1 or a bovine TGF β1.
[0041] In yet further embodiments, the IWR1 is present in an amount of about 2.5 μM; the EPZ004777 is present in an amount of about 3.3 μM; the forskolin is present in an amount of about 10 μM; the PD184352 is present in an amount of about 0.8 μM; the SU5402 is present in an amount of about 2 μM; the CHIR99021 is present in an amount of about 3 μM; and the human LIF or bovine LIF is present in an amount of 1000 U / mL. In still yet further embodiments, when BSA, bFGF and TGF β1 are present in the supplement, the BSA is present in an amount of about 1% (v / v); the human bFGF or bovine bFGF is present in an amount of about 100 ng / mL; and the human TGF β1 or bovine TGF β1 is present in an amount of about 1.74 ng / mL.
[0042] In yet another embodiment, the present disclosure relates to a method of producing stem cells. The method comprises the steps of:
[0043] a) providing bovine pre-implantation embryos;
[0044] b) treating the bovine pre-implantation embryos with an enzyme to remove the zone pellucida;
[0045] c) culturing treated bovine pre-implantation embryos with a composition to form a culture, the composition comprising:
[0046] i) a cell culture medium; and
[0047] ii) a supplement comprising:
[0048] a) a Wingless / Integrated (WNT) inhibitor;
[0049] b) a histone methyltransferase DOT1L inhibitor (iDOT1L);
[0050] c) an adenyl cyclase activator;
[0051] d) a Mitogen-activated protein kinase kinases 1 and 2 (MEK1 / 2) inhibitor;
[0052] e) a fibroblast growth factor receptor (FGFR) inhibitor;
[0053] f) a glycogen synthase kinase (GSK-3) inhibitor; and
[0054] g) a leukemia inhibitory factor (LIF); and
[0055] d) harvesting, collecting, or isolating stem cells resulting from the culture.
[0056] In some embodiments of the above method, the enzyme is a pronase, a hyaluronidase, an acrosin or any combinations thereof.
[0057] In some embodiments of the above method, the supplement further comprises: bovine serum albumin (BSA); a basic fibroblast growth factor (bFGF); and a transforming growth factor β1 (TGF β1).
[0058] In some embodiments of the above method, the culture medium used in the composition is a serum free culture medium for culturing stem cell lines. In other embodiments, the culture medium used in the composition is mTeSR-plus or N2B27.
[0059] In some embodiments of the above method, when the culture medium is N2B27, the supplement further comprises: bovine serum albumin (BSA); a basic fibroblast growth factor (bFGF); and a transforming growth factor β1 (TGF β1).
[0060] In still other embodiments of the above method, the composition comprises at least 99% of the cell culture medium and about 1% of the supplement.
[0061] In yet still other embodiments of the above method, the supplement in the composition comprises:
[0062] a) from about 0.1 μM to about 25 μM of the WNT inhibitor;
[0063] b) from about 0.1 μM to about 25 μM of the histone methyltransferase DOT1L inhibitor;
[0064] c) from about 0.1 μM to about 10 μM of the MEK1 / 2 inhibitor;
[0065] d) about 0.1 μM to about 10 μM of the FGFR inhibitor;
[0066] e) from about 0.5 μM to about 10 μM of the GSK-3 inhibitor;
[0067] f) from about 1 μM to about 50 μM of the adenyl cyclase activator; and
[0068] g) about 100 U / ml to about 5000 U / ml of LIF.
[0069] In some embodiments of the above method, when the supplement also comprises BSA, bFGF, and TGF β1, the supplement in the composition comprises: from about 0.01 to about 5% (v / v) of BSA; from about 10 to about 500 ng / ml of bFGF; and from about 0.1 to about 5 ng / ml of TGF β1.
[0070] In still further aspects of the above method, in the supplement:
[0071] a) the WNT inhibitor is IWR1;
[0072] b) the histone methyltransferase DOT1L inhibitor is EPZ004777;
[0073] c) the adenyl cyclase activator is forskolin;
[0074] d) the MEK1 / 2 inhibitor is PD 184352;
[0075] e) the FGFR inhibitor is SU5402;
[0076] f) the GSK-3 inhibitor is CHIR99021; and
[0077] g) the LIF is a human LIF or a bovine LIF.
[0078] In some embodiments of the above method, when the supplement also comprises BSA, bFGF, and TGF β1 : the bFGF is a human bFGF or a bovine bFGF; and the TGF β1 is a human TGF β1 or a bovine TGF β1.
[0079] In yet further embodiments of the above method, the IWR1 is present in an amount of about 2.5 μM; the EPZ004777 is present in an amount of about 3.3 μM; the forskolin is present in an amount of about 10 μM; the PD 184352 is present in an amount of about 0.8 μM; the SU5402 is present in an amount of about 2 μM; the CHIR99021 is present in an amount of about 3 μM; and the human LIF or bovine LIF is present in an amount of 1000 U / mL. In still yet further embodiments of the above method, when BSA, bFGF and TGF β1 are present in the supplement, the BSA is present in an amount of about 1% (v / v); the human bFGF or bovine bFGF is present in an amount of about 100 ng / mL; and the human TGF β1 or bovine TGF β1 is present in an amount of about 1.74 ng / mL.
[0080] In still other embodiments, also disclosed is a stem cell line comprising a bovine embryonic stem cell (bESC), wherein the bESC maintains its pluripotency and self-renewal capacity.
[0081] These and other aspects of the present invention are described in more detail below.BRIEF DESCRIPTION OF THE DRAWINGS
[0082] The accompanying drawings are included to provide a further understanding of the methods, compositions of the disclosure, and are incorporated in and constitute a part of this specification. The drawings illustrate one or more embodiment(s) of the disclosure, and together with the description serve to explain the principles and operation of the disclosure.
[0083] FIG 1: Derivation and characterization of bESCs in TiF2 medium. (A) Derivation of JY-bESCs cultured on feeder layers in TiF2 medium. (B) Colony morphology of JY-bESCs in TiF2 medium. (C) SSEA4 live staining of emerged colony from passaged bovine blastocyst (P2)in TiF2 medium. (D) Proliferation rate of JY-bESCs. Mean ± sd, n = 3. (E) Karyotypes of JY- bESC-1 and JY-bESC-4 at passages 63 and 64, respectively. (F) Relative pluripotent genes expression of bMSC and JY-bESCs at early (P8 to P12) and late (P42 to P50) passages. Mean ± sd, n = 3. (G) Representative immuno staining images of JY-bESCs in TiF2 medium for OCT4, NANOG, S0X2, SSEA3, SSEA4, TRA-1-60. (H) AP staining on JY-bESC-1 at passage 12. (I) Bisulfite sequencing analysis of the bovine 0CT4 distal enhancer (left 2 panels), proximal promoter (middle 2 panels) and NANOG promoter (right 2 panels) regions. Open and closed circles represent unmethylated and methylated CpGs, respectively. The percentage of methylated CpG is shown above each sample. (J) Immunostaining of passaged EBs derived from JY-bESCs for markers of the three germ layers (GATA4 for endoderm, SMA for mesoderm, and TUJ1 for ectoderm). (K) H&E staining of teratoma derived from JY-bESCs revealed representative tissues from the ectoderm (glial cells), mesoderm (cartilage), and endoderm (epithelial tissue with acinar complex).
[0084] FIG 2: Comparative Transcriptomic and X Chromosome Inactivation (Xi) Analyses of PSCs. (A) PCA comparison of JY-bESCs to previously published bovine embryos (ICM, APE, ERSE [GSE53387] and blastocyst [BL; GSE52415 and GSE110036]) and pluripotent stem cells (bpESC [GSE110036], bEPSC [GSE129760] and biPSC [GSE169624]). (B) Heatmap comparison of JY-bESC, biPSC_Pillai, and bpESC_Bogliotti. Key genes related to pluripotency are listed on the left. Significantly enriched Gene Ontology Biological Process (GO:BP) terms are displayed on the right. (C) Dot plots of marker genes representing different pluripotency states in four bovine PSCs: JY-bESC, bEPSC_Zhao, biPSC_Pillai, and bpESC_Bogliotti.(D) PCA plot of RNA-seq data from bovine, human, and mouse embryos and PSCs. Dot colors represent different cell types of various pluripotency states, while dot shapes indicate species. The gray arrows suggest changes in pluripotency within species. (E) PCA projection of JY- bESCs' pluripotency onto that of human PSCs. (F) 3D PCA plot of bovine, human, and mouse embryos and PSCs. Species differences are revealed in PC3. (G) XIST and HUWE1 RNA FISH signals and (H) representative H3K27me3 immuno staining images in female JY-bESCs before (top) and after (bottom) 6 additional passages. (I) Positive ratios of H3K27me3 and XIST in colonies established from single cells before and after an additional 6 passages. No significant difference (p > 0.05) was observed before and after the additional passages. The data were analyzed by Student’s t-test, n = 5. (J) X:A median expression ratios and 95% confidenceintervals of four JY-bESC lines. The lower line indicates failure of dosage compensation. (K) X:A allelic ratios of female JY-bESC-8 line.
[0085] FIG. 3: Direct in vitro Differentiation of bESCs to Neural Progenitor Cells (NPCs) and Primordial Germ Cell-Like Cells (PGCLCs). (A) The morphology of NPC 19 days after induction. (B) Representative immunostaining images of JY-bESCs derived NPC (upper row) and JY-bESCs (lower row) for SOX2, NESTIN, and PAX6. (C) Relative expression of NPC- related genes by JY-bESCs and the induced NPCs at D19. Mean ± sd, n = 2. (D) The morphology of PGCLCs four days after induction. (E) Relative expression of PGC-related genes by JY-bESCs and D4 PGCLC induced with BMP4, and BMP4 and BMP8a. Mean ± sd, n = 3. (F) Representative immuno staining images of PGCLCs and JY-bESCs for TFAP2C, PRDM1 and SOX17 four days after induction (first row: one layer of PGCLCs; second row: 3D projection of Z-stack scanning of PGCLCs; third row: JY-bESCs). (G) Representative immuno staining images of PGCLCs for H3K27me3, H3K9me2 and PRDM1 four days after induction.
[0086] FIG. 4: Chimeric Embryos Generated from bESCs carrying the GFP marker gene. (A) A representative mouse-bovine chimeric blastocyst 24 h after aggregation. (B) Whole-mount immunofluorescence of mouse-bovine chimeric blastocysts. (C) IHC staining of mouse-bovine E7.5 embryo using the GFP antibody. The arrows point to the positive regions. (D) Summary of PCR results on JY-bESCs' contribution in mouse chimeric embryo proper and decidua. (E) Bovine-bovine chimeric blastocysts developed from aggregated 8-cell (left) and morula stage (right) embryos. (F) Whole-mount immunofluorescence of bovine chimeric. (G) Day 25 bovine chimeric embryonic disc (the first and second rows) and extraembryonic tissue (the third row) with visible GFP signals. (H) UMAP clustering of all GFP+ cells from two D25 bovine fetuses and spiked-in cells from one extraembryonic sample. (I) Projection of GFP+ (GFP read count > 0) and GFP- (GFP read count = 0) cells in UMAP.
[0087] FIG. 5: Components screening and characterization of bESCs in TiF3 medium. (A) Morphological changes of bESCs in TiF2 medium with individual component elimination over three-days of culture. (B) The morphology of bESCs in TiF2 and TiF3 medium after five passages. (C) Relative expression of pluripotency genes by bESCs in TiF2 and TiF3 medium. Mean ± sd, n = 3. (D) Immuno staining of passaged EBs derived from JY-bESCs in TiF3 mediumfor markers of the three germ layers (GATA4 for endoderm, SMA for mesoderm, and TUJ1 for ectoderm).
[0088] FIG. 6: Derivation and Characterization of bESCs. (A) Relative expression of pluripotency genes by biPSCs in TiF and TiF2 medium. Mean ± sd, n = 3. (B) The morphology of biPSCs in TiF2 medium. (C) Flow cytometry analysis of CRIPSR-Cas9 edited JY-bESCs with GFP and frame-corrected Cas9 reporter (top right). (D) JY-bESC GFP+ line with Cas9 out-of- frame reporter after CRISPR-Cas9 editing. (E) EBs formed by JY-bESCs. (F) Negative control immuno staining of JY-bESCs with only secondary antibodies. (G) Negative control immuno staining of EBs with only secondary antibodies. (H) A representative teratoma formed by JY-bESCs. (I) One layer of the Z-stack scanning for immunostaining images of PGCLCs for TFAP2C, PRDM1 and SOX17 four days after induction (Z = 18).
[0089] FIG. 7: Comparative Transcriptomic Analysis of PSCs. (A) PCA comparison of JY- bESCs to previously published bovine embryos (ICM, APE, ERSE [GSE53387] and blastocyst [BL; GSE52415 and GSE110036]). (B) Heatmap of pluripotency markers across four mouse cell lines: mESC_Yang (mouse naive ESC [GSE89303]), mpESC_Liu (mouse primed ESC [GSE92635]), mFormative_Kinoshita (mouse formative ESC [GSE131556]), and mEPSC_Yang (mouse extended ESC [GSE89303]). (C) Heatmap of pluripotency markers across four human cell lines: hnESC_Bi (human naive ESC [GSE174771]), hpESC_Bi (human primed ESC [GSE174771]), hFormative_Yu (human formative [GSE135989]), and hEPSC_Yang (human extended ESC [GSE89303]). (D) Heatmap comparison of DEGs between JY-bESCs and bMSCs (GSE18O931).
[0090] FIG. 8: Comparative Transcriptomic Analysis of PSCs. (A) PCA projection of eY- bESCs' pluripotency onto that of mouse PSCs. (B) Heatmap comparison of JY-bESCs, hFormatives_Kioshita (GSE131551), and mFormatives_Kioshita (GSE131556). Key genes related to pluripotency are listed on the left. Significantly enriched GO:BP terms are displayed on the right. (C) Heatmap comparison of JY-bESCs, hpESC_Bi (GSE174771), and mpESC_Liu (GSE92635). Key genes related to pluripotency are listed on the left. Significantly enriched GO:BP terms are displayed on the right. (D) Venn diagram showing the overlap of unique genes in JY- bESCs and bovine embryos. JY-bESCs unique genes were identified through a comparative analysis of JY-bESCs, hFormatives_Kinoshita, and mFormatives_Kinoshita. Bovine embryo unique genes were identified by comparing previously published RNA-seq data of bovine, human,and mouse embryos. Differential gene expression analysis was performed between each pair within their respective three groups, identifying genes that were highly expressed exclusively in JY-bESCs or bovine embryos as unique genes.
[0091] FIG. 9: Species- specific Metabolic Pathway Analysis. (A) Bar plot of KEGG pathways enriched by the top 2,000 genes primarily contributing to the variance of PC3 in the 3D PCA. (B- F) Boxplot of Log2(TPM+l) expression levels for genes involved in various KEGG pathways across different species (cattle, human, and mouse), identified via KEGG analysis of the top 500 genes primarily contributing to PC3 in PCA. (B) Carbon Metabolism; (C) N-glycan Biosynthesis, (D) Reactive Oxygen Species Processes, (E) Biosynthesis of Cofactors, and (F) Purine Synthesis. Cattle (n = 31), human (n = 19), and mouse (n = 25). (G) Boxplot of Log2(TPM+l) expression levels for genes involved in glycerolipids across different species (cattle, human, and mouse). (H) Barplot of Log2(TPM+l) expression levels of TPI1 and GPD1 in different bovine embryos and PSCs.
[0092] FIG. 10: X Chromosome Inactivation (XCI) Analysis of PSCs. (A) Karyotypes of JY- bESC-8 displaying two X chromosomes. (B) Comparison of the sum of five Y-linked genes (OFD1Y, USP9Y, ZRSR2Y, DDX3Y, and EIF2S3Y) between a female line (JY-bESC-8) and three male lines (JY-bESC-1, JY-bESC-3, JY-bESC-4). (C) Expression of the XIST gene in four JY-bESC lines.
[0093] FIG. 11: Inter- and Intra-species Chimeric Embryos Generated from JY-bESCs. (A) E7.5 and E8.5 mouse-bovine chimeric embryos generated with GFP positive bESCs. (B) Serial IHC staining images of E7.5 mouse-bovine chimeric embryo using the GFP antibody. The arrows point to the positive regions. (C) PCR analysis of JY-bESCs' contribution in E7.5 and 8.5 mouse decidual tissues and embryo proper using bovine- or mouse- specific primers. (D) Additional images of whole-mount immunofluorescence of bovine chimeric blastocysts. (E) A flushed Day 25 bovine chimeric embryo showing the fetus and extraembryonic tissue. Each square = 16x16 mm. (F) Flow cytometry analysis of GFP positive (P4) and negative (P5) cells in Day 25 in vivo developed bovine chimeric fetuses.
[0094] FIG. 12: 10x scRNA-seq Analysis. (A) Dot plot of expression levels of representative markers in each cluster. (B) Pie chart of the proportions of different cell types in GFP+ cells of two Day 25 bovine chimeric embryos. (C) Heatmap of the DEGs from different cell types s in GFP+ cells of two Day 25 bovine chimeric embryos.DETAILED DESCRIPTION
[0095] Provided herein are compositions and methods for producing bovine pluripotent stem cells (bPSCs), including bovine embryonic stem cells (bESCs), bovine induced pluripotent stem cells (biPSCs), and bovine expanded potential stem cells (bEPSCs).
[0096] In one embodiment, provided herein arc compositions. In some embodiments, the compositions comprise a cell culture media. In some embodiments, the cell culture medium can be used in methods for generating bPSCs (such as bESCs, biPSCs, and bEPSCs). In some embodiments, the cell culture medium further comprises a suitable serum-free, commercially available stem cell culture medium, such as mTeSR™, mTeSR™-plus (available from StemCell Technologies), or N2B27. The mTeSR™, mTeSR™-plus media are based on the mTeSR™ 1 formulation (described in Ludwig TE et al. (2006). Any suitable serum-free stem cell culture medium can be used in the composition. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 24(2): 185-7 and Ludwig TE et al. (2006) Feeder- independent culture of human embryonic stem cells. Nat Methods 3(8): 637-46)). The N2B27 medium comprises Dulbecco's Modified Eagle Medium / Nutrient Mixture F-12 (DMEM / F12) and Neurobasal medium combined with a N2 supplement (such as that commercially available from Thermo Scientific) and a B27 supplement (available from Thermo Scientific).
[0097] In some embodiments, in addition to the cell culture medium, the compositions also comprise one or more supplements. In an embodiment, the composition includes at least 90% to 99.9% (v / v) of the cell culture medium. In some embodiments, the composition includes at least 99% (v / v) of the cell culture medium and about 1% (v / v) of a supplement. In an embodiment, the composition includes at least 99% to 99.9% (v / v) of the cell culture medium. For example, the composition includes at least 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or at least 99.9% (v / v) of the cell culture medium. In an embodiment, the composition includes about 0.1% to about 1% (v / v) of the supplement. For example, the composition includes about 0.1%, 0.2%, 0,3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, or about 0.9% (v / v) of the supplement.
[0098] In some embodiments, the supplement is a fibroblast growth factor receptor (FGFR) inhibitor. The phrase “fibroblast growth factor receptor (FGFR) inhibitor” refers to an agent (e.g., such as a small molecule, peptide, protein, biologic or any combination thereol) that inhibits the FGF / fibroblast growth factor receptor (FGFR) pathway. Fibroblast growth factorreceptors are the receptors that bind members of the fibroblast growth factor family of proteins and some of these receptors arc involved in pathological conditions, such as cancer. An example of a FGFR inhibitor that can be used includes SU5402 having the chemical name 2-[(1,2- dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-1H-pyrrole-3-propanoic acid and the below structure:
[0099] In some embodiments, the composition comprises the FGFR inhibitor at a concentration of about 0.1 μM to about 10 μM. In some embodiments, the composition comprises the FGFR inhibitor at a concentration of about 1 μM to about 5 μM. For example, in some embodiments, the composition comprises the FGFR inhibitor at a concentration of about 0.1 μM, about 0.5 μM, about 0.75 μM, about 1 μM, about 2 μM, about 3 μM, about 4 μM, about 5 μM, about 6 μM, about 7 μM, about 8 μM, about 9 μM, about 10 μM. In some embodiments, the composition comprises the FGFR inhibitor at a concentration of about 2 μM.
[0100] In addition to the FGFR inhibitor, the composition can further comprise the supplements bovine serum albumin (BSA), a basic fibroblast growth factor (bFGF), and transforming growth factor β1 (TGF β1). In some embodiments, the bFGF is human bFGF or bovine bFGF. In some embodiments, the TGF β1 is human TGF β1 or bovine TGF β1.
[0101] In some embodiments, the BSA, bFGF and TGF β1 can be supplied by the cell culture medium. For example, certain serum-free, commercially available stem cell culture medium, such as mTeSR™, mTeSR™-plus, may contain BSA, bFGF and TGF β1 in suitable amounts for use in the compositions described herein. Alternatively, in some embodiments, the BSA, bFGF and TGF β1 can be added as a supplement to the composition. In some embodiments, the amount of BSA used is from about 0.01 to about 5% (v / v). In other embodiments, the amount of BSA used is from about 0.1 to about 2% (v / v). In still other embodiments, the amount of BSA used is about 1% (v / v). In some embodiments, the amount of bFGF used is from about 10 to about 500 ng / mL. In still other embodiments, the amount of bFGF used is from about 20 to about 200 ng / mL. In still other embodiments, the amount ofbFGF used is about 100 ng / mL. In still other embodiments, the amount of TGF β1 used is from about 0.1 to about 5 ng / mL. In still other embodiments, the amount of TGF β1 used is from about 0.5 to about 3 ng / mL. In yet still other embodiments, the amount of TGF β1 used is about 1.74 ng / mL.
[0102] At a minimum, the compositions described herein comprise a cell culture medium and a FGFR inhibitor and, if not supplied by the cell culture medium, BSA, bFGF, and TGF β1. In some embodiments, the composition can also contain one or more of the following additional supplements: Wingless / Integrated (WNT) inhibitor, a histone methyltransferase DOT1L inhibitor, an adenyl cyclase activator, a mitogen-activated protein-kinase kinases 1 and 2 (MEK1 / 2) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, a leukemia inhibitor factor (LIF), or any combination thereof. In some embodiments, the composition contains two or more of a WNT inhibitor, a histone methyltransferase DOT1L inhibitor, an adenyl cyclase activator, a mitogen-activated protein-kinase kinases 1 and 2 (MEK1 / 2) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, a leukemia inhibitor factor (LIF), or any combination thereof. In some embodiments, the composition contains three or more of a WNT inhibitor, a histone methyltransferase DOT1L inhibitor, an adenyl cyclase activator, a mitogen-activated protein- kinase kinases 1 and 2 (MEK1 / 2) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, a leukemia inhibitor factor (LIF), or any combination thereof. In some embodiments, the composition contains four or more of a WNT inhibitor, a histone methyltransferase DOT1L inhibitor, an adenyl cyclase activator, a mitogen-activated protein-kinase kinases 1 and 2 (MEK1 / 2) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, a leukemia inhibitor factor (LIF), or any combination thereof. In some embodiments, the composition contains five or more of a WNT inhibitor, a histone methyltransferase DOT1L inhibitor, an adenyl cyclase activator, a mitogen-activated protein-kinase kinases 1 and 2 (MEK1 / 2) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, a leukemia inhibitor factor (LIF), or any combination thereof. In yet other embodiments, the composition contains a WNT inhibitor, a histone methyltransferase DOT1L inhibitor, an adenyl cyclase activator, a mitogen-activated protein-kinase kinases 1 and 2 (MEK1 / 2) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, and a leukemia inhibitor factor (LIF).
[0103] Any suitable WNT inhibitor may be used in the composition. The terms “WNT inhibitor” WNT pathway inhibitor”, and “WNT signaling inhibitor” are used interchangeablyherein to refer to an agent that inhibits one or more aspects of the WNT signaling pathway. Tn some embodiments, the WNT inhibitor impacts one or more components of the canonical Wnt / p- catenin signaling pathway. In some embodiments, the WNT inhibitor is a small molecule inhibitor. In some embodiments, the WNT inhibitor is selected from XAV-939, Wnt-C59, IWR1, ICG-001, IWP-2, LGK-974, CCT251545, FHF 535, IPW-4, JW 67, JW 74, KYA 1797K, NLS-StAx-H, TAK 715, WIC1, and derivatives thereof. In some embodiments, the WNT inhibitor is IWR1 or a derivative thereof. IWR1 is also referred to as IWR-l-endo, endo-IWR 1, or IRW-1 and has the structure:
[0104] In some embodiments, the composition comprises more than one WNT inhibitor. For example, in some embodiments the composition comprises two, three, four, or more than four WNT inhibitors. In some embodiments, the composition comprises a combination of two or more WNT inhibitors selected from XAV-939, Wnt-C59, IWR1, ICG-001, IWP-2, LGK-974, CCT251545, FHF 535, IPW-4, JW 67, JW 74, KYA 1797K, NLS-StAx-H, TAK 715, WIC1, and derivatives thereof.
[0105] In some embodiments, the composition comprises the WNT inhibitor at a concentration of about 0.1 μM to about 25 μM. In some embodiments, the composition comprises the WNT inhibitor at a concentration of about 1 μM to about 20 μM. For example, in some embodiments, the composition comprises the WNT inhibitor at a concentration of about 1 μM, about 2 μM, about 3 μM, about 4 μM, about 5 μM, about 6 μM, about 7 μM, about 8 μM, about 9 μM, about 10 μM, about 11 μM, about 12 μM, about 13 μM, about 14 μM, about 15 μM, about 16 μM, about 17 μM, about 18 μM, about 19 μM, or about 20 μM. In some embodiments, the composition comprises the WNT inhibitor at a concentration of about 0.1 μM to about 10 μM. In some embodiments, the composition comprises the WNT inhibitor at a concentration of about 0.5 to about 5 μM. In some embodiments, the composition comprises the WNT inhibitor at a concentration of about 2.5 μM. Tn some embodiments, the composition comprises the WNT inhibitor at a concentration of about 5 μM to about 15 μM. In someembodiments, the composition comprises the WNT inhibitor at a concentration of about 8 μM to about 12 μM. In some embodiments, the composition comprises the WNT inhibitor at a concentration of about 10 μM.
[0106] In other embodiments, the composition comprises a DOT1L inhibitor. The term “DOT1L inhibitor” refers to an inhibitor of the histone methyltransferase DOT1L, which methylates H3K79 using S-adenosyl-L-methionine (SAM) as a co-factor. Any suitable DOT1L inhibitor may be used. In some embodiments, the DOT1L inhibitor is a SAM competitive inhibitor of DOT1L. In some embodiments, the DOT1L inhibitor is a small molecule inhibitor. In some embodiments, the DOT1L inhibitor is EPZ004777 (also referred to herein as “iDOT1L”) or a derivative thereof. EPZ004777 has the chemical name 7-[5-Deoxy-5-[[3-[[[[4-(1,1- dimethylethyl)phenyl]amino]carbonyl]amino]propyl](l-methylethyl)amino]-P-D-ribofuranosyl]- 7H-pyrrolo[2,3-d] pyrimidin-4-amine Formic Acid Salt, and the structure:
[0107] In some embodiments, the DOT1L inhibitor is EPZ-5676 or a derivative thereof.EPZ-5675 is also referred to as pinometostat, and has the chemical name (2R,3R,4S,5R)-2-(6- amino-9H-purin-9-yl)-5-((((1R,3S)-3-(2-(5-(tert -butyl)-1H-benzo[d]imidazol-2- yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and the structure:
[0108] In some embodiments, the composition comprises more than one DOT1L inhibitor.For example, in some embodiments the composition comprises two DOT1L inhibitors.
[0109] In some embodiments, the composition comprises the DOT1L inhibitor (e.g. EPZ004777, EPZ-5676) at a concentration of about 0.5 μM to about 30 μM. In some embodiments, the composition comprises the DOT1L inhibitor at a concentration of about 1 μM to about 25 μM. In some embodiments, the composition comprises the DOT1L inhibitor at a concentration of about 1 μM to about 10 μM. In some embodiments, the composition comprises the DOT1L inhibitor at a concentration of about 1 μM to about 5 μM. For example, in some embodiments the composition comprises the DOT1L inhibitor at a concentration of about 1 μM, about 2 μM, about 3 μM, about 4 μM, or about 5 μM. In some embodiments, the composition comprises the DOT1L inhibitor at a concentration of about 1 μM, about 1.5 μM, about 2 μM, about 2.5 μM, about 2.6 μM, about 2.7 μM, about 2.8 μM, about 2.9 μM, about 3 μM, about 3.1 μM, about 3.2 μM, about 3.3 μM, about 3.4 μM, about 3.5 μM, about 3.6 μM, about 3.7 μM, about 3.8 μM, about 3.9 μM, about 4 μM, about 5.5 μM, or about 5 μM. In some embodiments, the DOT1L inhibitor is EPZ004777.
[0110] In yet other embodiments, the composition comprises a leukemia inhibitory factor (LIF). The LIF used in the composition can be human LIF or bovine LIF or a combination thereof. In some embodiments, the LIF is human LIF. In other embodiments, the LIF is bovine LIF. In some embodiments, the cell culture medium comprises about 100 U / mL to about 5000 U / mL human LIF or bovine LIF. In some embodiments, the cell culture medium comprises about 100 U / mL to about 2000 U / mL human LIF. In some embodiments, the cell culture medium comprises about 100 U / ml, about 200 U / mL, about 300 U / ml, about 400 U / mL, about 500 U / ml, about 600 U / mL, about 700 U / ml, about 800 U / mL, about 900 U / ml, about 1000 U / mL, about 1100 U / ml, about 1200 U / mL, about 1300 U / ml, about 1400 U / mL, about 1500 U / ml, about 1600 U / mL, about 1700 U / ml, about 1800 U / mL, about 1900 U / ml, or about 2000 U / mL human LIF or bovine LIF. In some embodiments, the cell culture medium comprises 1000 U / mL human LIF or bovine LIF.
[0111] In still further embodiments, the composition comprises at least one glycogen synthase kinase 3 (GSK-3) inhibitor. In some embodiments, the GSK-3 inhibitor is a small molecule inhibitor. In some embodiments, the GSK-3 inhibitor is selected from CHIR-99021, CHIR-98014, LY2090314, BIO, TWS119, Tideglusib, SB216763, and derivatives thereof. In some embodiments, the GSK-3 inhibitor is CHIR-99021 or a derivative thereof. CHIR-99021 is also referred to as Laduviglusib, and has the structure:
[0112] In some embodiments, the composition comprises the GSK-3 inhibitor at a concentration of about 0.5 μM to about 10 μM. In some embodiments, the composition comprises the GSK-3 inhibitor at a concentration of about 1 μM to about 5 μM. For example, in some embodiments the composition comprises the GSK-3 inhibitor at a concentration of about 1 μM, about 2 μM, about 3 μM, about 4 μM, or about 5 μM. In some embodiments, the composition comprises the GSK-3 inhibitor at a concentration of about 1 μM, about 1.5 μM, about 2 μM, about 2.5 μM, about 2.6 μM, about 2.7 μM, about 2.8 μM, about 2.9 μM, about 3 μM, about 3.1 μM, about 3.2 μM, about 3.3 μM, about 3.4 μM, about 3.5 μM, about 3.6 μM, about 3.7 μM, about 3.8 μM, about 3.9 μM, about 4 μM, about 5.5 μM, or about 5 μM. In some embodiments, the GSK-3 inhibitor is CHIR-99021.
[0113] In yet still other embodiments, the composition comprises at least one mitogen- activated protein kinase inhibitor. In some embodiments, the at least one mitogen-activated protein kinase inhibitor inhibits MEK1 / 2 (i.e. inhibits MEK1 and MEK2). In some embodiments, the MEK 1 / 2 inhibitor is selected from Trametinib, PD0325901 , Selumetinib, UO126-EtOH, PD989059, and derivatives thereof. In some embodiments, the MEK1 / 2 inhibitor is PD0325901 or a derivative thereof. PD0325901 is also referred to as Mirdametinib, and has the structure:
[0114] In some embodiments, the composition comprises the MEK1 / 2 inhibitor at a concentration of about 0.1 μM to about 10 μM. In some embodiments, the compositioncomprises the MEK1 / 2 inhibitor at a concentration of about 0.25 μM to about 7.5 μM. In some embodiments, the composition comprises the MEK1 / 2 inhibitor at a concentration of about 0.5 μM to about 5 μM. In some embodiments, the composition comprises the MEK1 / 2 inhibitor at a concentration of about 0.75 μM to about 2.5 μM. In some embodiments, the composition comprises the MEK1 / 2 inhibitor at a concentration of about 1 μM. In some embodiments, the composition comprises the MEK1 / 2 inhibitor at a concentration of about 0.1 μM, about 0.2 μM, about 0.3 μM, about 0.4 μM, about 0.5 μM, about 0.6 μM, about 0.7 μM, about 0.8μM, about 0.9 μM, about 1.0 μM, about 1.1 μM, about 1.2 μM, about 1.3 μM, about 1.4 μM, about 1.5 μM, about 1.6 μM, about 1.7 μM, about 1.8 μM, about 1.9 μM, about 2.0 μM, about 2.1 μM, about 2.2 μM, about 2.3 μM, about 2.4 μM, or about 2.5 μM. In some embodiments, the MEK1 / 2 inhibitor is PD0325901.
[0115] In still further embodiments, the composition comprises an adenyl cyclase activator. In some embodiments, the adenyl cyclase activator is Forskolin. In some embodiments, the composition comprises the adenyl cyclase activator (e.g. Forskolin) at a concentration of about 0.1 μM to about 20 μM. In some embodiments, the composition comprises the adenyl cyclase activator (e.g. Forskolin) at a concentration of about 1 μM to about 15 μM. In some embodiments, the composition comprises the adenyl cyclase activator (e.g. Forskolin) at a concentration of about 1 μM, about 2 μM, about 3 μM, about 4 μM, about 5 μM, about 6 μM, about 7 μM, about 8 μM, about 9 μM, about 10 μM, about 11 μM, about 12 μM, about 13 μM, about 14 μM, or about 15 μM. in some embodiments, the composition comprises about 10 μM Forskolin.
[0116] In some embodiments, disclosed herein is a composition (also called as TiF2 medium) which can be used to derive, grow and maintain the pluripotency and self-renewal capacity of a cell line, such as bovine embryonic stem cells (bESCs), bovine induced pluripotent stem cells (biPSCs), and bovine expanded potential stem cells (bEPSCs).
[0117] In an embodiment, the composition (e.g., TiF2) includes a cell culture medium such as mTeSR-plus media which supplies BSA, bFGF, and TGF β1, and the following supplements: a WNT inhibitor (such as IWR1); a histone methyltransferase DOT1L inhibitor (such as EPZ004777); an adenyl cyclase activator (such as forskolin); a MEK1 / 2 inhibitor (such as PD 184352); a FGFR inhibitor (such as SU5402); a GSK-3 inhibitor (such as CHIR99021); and a LIF (such as a human or bovine LIF).
[0118] In some embodiments, the TiF2 medium comprises a mTesR-plus media (which contains BSA, bFGF and TGF β1) and the supplements:
[0119] a) IWRl;
[0120] b) EPZ004777;
[0121] c) forskolin;
[0122] d) PD 184352;
[0123] e) SU5402;
[0124] f)CHIR99021; and
[0125] g) human LIF or a bovine LIF.
[0126] In yet other embodiments, disclosed is a composition (also called as TiF3 medium) to derive, grow and maintain the pluripotency and self-renew capacity of a cell line, such as bovine embryonic stem cells (bESCs), bovine induced pluripotent stem cells (biPSCs), and bovine expanded potential stem cells (bEPSCs). This composition (e.g., TiF3) includes: a cell culture medium (such as N2B27 media); a WNT inhibitor (such as IWR1); a histone methyltransferase DOT1L inhibitor (such as EPZ004777); an adenyl cyclase activator (such as forskolin); a MEK1 / 2 inhibitor (such as PD 184352); a FGFR inhibitor (such as SU5402); a GSK-3 inhibitor (such as CHIR99021); a LIF (such as a human or bovine LIF); BSA, a bFGF (such as human or bovine bFGF); and a TGF β1 (such as human or bovine TGF β1).
[0127] In some embodiments, the TiF3 medium comprises a N2B27 media and the supplements:
[0128] a) IWRl;
[0129] b) EPZ004777;
[0130] c) forskolin;
[0131] d) PD 184352;
[0132] e) SU5402;
[0133] f) CHIR99021;
[0134] g) human LIF or a bovine LIF;
[0135] h) BSA;
[0136] i) human bFGF or a bovine bFGF; and
[0137] j) human TGF β1 or a bovine TGF β1.
[0138] In some embodiments, the TiF2 and TiF3 media contain from about 0.1 μM to about 25 μM of a WNT inhibitor; from about 0.1 μM to about 25 μM of a histone mcthyltransfcrasc DOT1L inhibitor; from about 0.1 μM to about 10 μM of a MEK1 / 2 inhibitor; about 0.1 μM to about 10 μM of a FGFR inhibitor; from about 0.5 μM to about 10 μM of a GSK-3 inhibitor; from about 1 μM to about 50 μM of an adenyl cyclase activator; about 100 U / ml to about 5000 U / ml of LIF, from about 0.01 to about 5% of BSA (v / v); from about 10 to about 500 ng / ml of bFGF; and from about 0.1 to about 5 ng / ml of TGF β1.
[0139] In still other embodiments, the TiF2 and TiF3 media contain from about 0.1 to about 10 μM or from about 0.1 to about 5 μM of a WNT inhibitor; from about 0.1 to about 10 μM or from about 0.1 to about 5 μM of a histone methyltransferase DOT1L inhibitor; from about 0.1 to about 2 μM of a MEK1 / 2 inhibitor; from about 0.1 to about 5 μM of a FGFR inhibitor; from about 0.5 to about 5 μM of a GSK-3 inhibitor; from about 5 to about 20 μM, or from about 5 to about 15 μM of an adenyl cyclase activator; from about 100 to about 2000 U / ml of LIF, from about 0.1 to about 2% of BSA (v / v); from about 20 to about 200 ng / ml of bFGF; and from about 0.5 to about 3 ng / ml of TGF β1.
[0140] In still other embodiments, the TiF2 and TiF3 media contain about 2.5 μM of a WNT inhibitor; about 0.8 μM of a MEK1 / 2 inhibitor; about 2 μM of a FGFR inhibitor; and about 3 μM of a GSK-3 inhibitor; about 3.3 μM of a DOTIL inhibitor; about 10 μM of an adenyl cyclase activator; about 1000 U / ml of a LIF, about 1% of BSA (v / v), about 100 ng / ml of bFGF and about 1.74 ng / ml of TGF pl.
[0141] Both the TiF2 and TiF3 media can be used to maintain the pluripotency and self- renew capacity of a cell line. In some embodiments, the cell line includes pluripotent stem cells. In other embodiments, the pluripotent stem cells are bovine embryonic stem cells (bESCs), bovine induced pluripotent stem cells (biPSCs), and bovine expanded potential stem cells (bEPSCs). In still other embodiments, the bovine embryonic stem cells have specific application in bovine and biomedical research. Moreover, the TiF2 and TiF3 media described herein provide improved pluripotency and colony morphology compared to the TiF media known in the art and described in WO 2023 / 122571. Specifically, the TiF2 and TiF3 media are capable of sustaining a normal bovine embryonic stem cell phenotype, such as remaining in an un-natural state of un-differentiation following single-cell passaging for more than eighty passages (at least nine months of in vitro culturing) made using the methods described herein.
[0142] In another embodiment, provided herein are methods for producing stem cells, such as bovine PSCs, such as bovine embryonic stem cells (bESCs), bovine induced pluripotent stem cells (biPSCs), and bovine expanded potential stem cells (bEPSCs). In some embodiments, provided herein are bESCs. In some embodiments, provided herein are biPSCs. In yet other embodiments, provided herein are bEPSCs. In some embodiments, the, the bPSCs, such as the bESCs, biPSCs and / or bEPSCs, are produced by a method described herein.
[0143] The methods for producing bovine PSCs involve obtaining or providing bovine pre- implantation embryos. The bovine pre-implantation embryos can be obtained or provided using techniques known in the art. Once bovine pre-implantation embryos are obtained or provided, the pre-implantation embryos are treated with at least one enzyme to remove the zone pellucida. Any enzyme that is capable of removing the zone pellucida can be used. In some embodiments, the enzyme is pronase, a hyaluronidase, an acrosin or any combinations thereof. Once the zone pellucida is removed, the treated (namely, enzyme treated) embryos are cultured on composition as described herein, such as, for example, a TiF2 or TiF3 composition. The bovine PSCs are then harvested, collected and / or isolated from the culture using techniques known in the art.
[0144] In an aspect, disclosed is a stem cell line including a bESC (such as a bESC, biPSC, and / or bEPSC), wherein the bESC maintains pluripotency. In an aspect, disclosed is a bovine embryonic stem cell line being capable of sustaining a normal bovine PSC phenotype such as the un-natural morphology of dome-shaped colonies in vitro cultured for at least eight months in vitro. In an aspect, disclosed is a bovine embryonic stem cell line being capable of sustaining the un-natural property of single-colony expansion in vitro following at least nine months of in vitro culturing. For example, a bovine embryonic stem cell line being capable of sustaining the un- natural property of single-colony expansion in vitro following about 10 months, about 11 months, about 12 months, about 13 months, about 14 months, or about 14 months of in vitro culturing.
[0145] In an aspect, disclosed is a bovine embryonic stem cell line being capable of sustaining a normal bovine embryonic stem cell phenotype such as remaining in an un-natural state of un-differentiation following single-cell passaging for more than eighty passages (at least nine months of in vitro culturing) made by the method disclosed herein. In an aspect, disclosed is a bovine embryonic stem cell line capable of sustaining a normal bovine embryonic stem cellphenotype following single-cell passaging for more than eighty passages (at least nine months of in vitro culturing) made by using the composition disclosed herein.
[0146] In an embodiment, the JY-bESCs (which are derived from bovine pre-implantation embryos, see Example 4) disclosed herein can be passaged from single cells. In an embodiment, the JY-bESCs disclosed herein show a doubling time of about 15 hours to about 25 hours. For example, the JY-bESCs disclosed herein show a doubling time of about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, or about 25 hours. In an embodiment, the JY-bESCs disclosed herein show a doubling time of about 19.12+0.84 hours. In an embodiment, the JY- bESCs disclosed herein can spontaneously differentiate into three germ layers in vitro and in vivo. In an embodiment, the JY-bESCs disclosed herein can be directly induced to neural progenitor cells (NPCs) and primordial germ cell-like cells (PGCLCs). In an embodiment, the JY-bESCs show high incorporation rate to mouse-bovine chimeric embryos. In an embodiment, the JY-bESCs show high incorporation rate to bovine chimeric embryos and have great potential to generate germline chimeric embryos. In certain embodiments, the JY-bESCs can be used to generate interspecies and intraspecies chimeric embryos by aggregating with ZP-free embryos.
[0147] In some embodiments, the method involves obtaining or providing bovine pre- implantation embryos. Such bovine pre-implantation embryos can be generated and obtained using techniques known in the art. Once such bovine pre-implantation embryos are obtained or provided, the zone pellucida is removed from the embryos by treating the embryos with an enzyme. An example of enzymes that can be used to remove the zone pellucida is a pronase, hyaluronidase, acrosin or any combinations thereof. Once the zone pellucida is removed, the zone pellucida-free embryos can be cultured on compositions described herein. For example, in some embodiments, the zone pellucida-free embryos can be cultured with a TiF2 medium. In other embodiments, the zone pellucida-free embryos can be cultured with a TiF3 medium. In still other embodiments, the medium can be replaced daily, every other day, every third day, every fourth day, or every fifth day.
[0148] The zone pellucida-free embryos are cultured on the compositions described herein, such as, for example, a TiF2 or TiF3 media, for as long as necessary to obtain bESCs, biPSCs and / or bEPSCs, (e.g. harvest). The cells may then be cultured in the compositions described herein (e.g., the TiF2 or TiF3 media) for a suitable duration (e.g. number of days or number ofpassages) until bovine induced pluripotent stem cells are generated. Successful generation of bESCs, biPSCs and / or bEPSCs, can be verified by measuring expression of gcncs / markcrs in the cells, including pluripotent markers such as OCT4, NANOG, LIN28A / B, SALL4, DNMT3A / 3B.
[0149] Unlike other methods known in the art, such as, for example, those described in WO 2023 / 122571, the methods described herein do not require any reprogramming the stem cell, such as a bovine mesenchymal stem cell. In some methods, reprogramming of the stem cell is required by overexpressing a plurality of reprogramming factors using techniques known in the art. Not having to reprogram the stem cells saves time and cost thus making the methods described herein cost effective and efficient compared to other methods known in the art. The bovine embryonic stem cells produced as described herein can be used for a number of applications, such as, for example, in cultured meat production and clinical trials.
[0150] The present disclosure is illustrated and further described in more detail with reference to the following non-limiting examples. Section headings as used in this section and the entire disclosure herein are merely for organizational purposes and are not intended to be limiting.EXAMPLES
[0151] Materials and Methods
[0152] Example 1: Bovine Embryo Production and Culture
[0153] Generating bESC from blastocysts by in vitro fertilization (IVF). Bovine cumulus oocyte complexes (COCs) were purchased from commercial vendors. The maturation process was conducted in the HEPES-buffered IVM medium at 38.5°C during shipping. Twenty-one to 24 h after maturation, COCs were transferred to BO-IVF medium in 4-well dishes covered with mineral oil and incubated in a 38.5°C incubator under 5.5% CO2. Frozen bovine semen was used for in vitro fertilization. The straws were thawed in a 37°C-water bath for 1-2 min and washed twice by centrifugation at 328 g for 5 min. The supernatant was discarded, and a final concentration of 1x106sperm was added (Day 0) to each IVF well at 38.5°C and 5.5% CO2for 16-20 h. The remaining cumulus cells of the presumptive zygotes were removed by incubating 1 ml 0.76 mg / ml hyaluronidase for 2 min at 38.5°C. After digestion, 800 pl supernatant was discarded, and the precipitated embryos were vortexed for 5 min to denude embryos. Denudedembryos were rinsed three times in BO-wash and collected in BO-IVC culture droplets. Embryos were incubated at 38.5°C, 5.5% CO2, and 6% O2for further development.
[0154] Example 2: Derivation and Culture of bESCs
[0155] Bovine blastocysts produced by IVF from Day 7 to 8 were used for bESC derivation. Unhatched blastocysts were treated with freshly made 2 mg / mL Pronase (Merck Millipore, 10165921001) at 38.5 °C for 2 min to remove the zona pellucida (ZP) and then thoroughly washed in in vitro culture (IVC) medium three times to remove traces of the enzyme. ZP-free blastocysts were transferred to a 24- well plate with mitomycin C treated MEF feeders in TiF2 medium that contains mTeSR-plus media (STEMCELL Technologies, 100-0276) supplemented with 2.5 μM IWR1 (AOBIOUS, AOB33702), 3.3 μM iDOT1L (AOBIOUS, AOB1922), 0.8 μM PD184352 (ApexBio, A1792), 2 μM SU5402 (ApexBio, A3843), 3 μM CHIR99021 (AOBIOUS, AOB3866), 10 μM Forskolin (AOBIOUS, AOB6380), and 1,000 U / ml human LIF (R&D Systems, 7734LF025), with the presence of 10 μM ROCKi (AOBIOUS, AOB3877) and incubated at 37°C and 5% CO2for 48h without disruption. After 7-8 days, the outgrowths of the embryos were passaged using TrypLE Express (Gibco, 12604013) to a 12-well plate with feeder layer in the presence of 10 μM ROCKi. The distinguishable dome-shaped colonies started to appear from P1 to P2 and were evaluated by SSEA4 live staining. The SSEA4-positive cells were sorted using a BD FACSAria II Cell Sorter (BD Bioscience) and replated to fresh feeder layer with 10 μM ROCKi. Then the bESCs were passaged every three days at a ratio of 1:8 to 1:6 by TrypLE Express in TiF2 medium with 10 μM ROCKi. TiF3 medium contains N2B27 medium supplemented with 2.5 μM IWR1, 3.3 μM iDOT1L, 0.8 μM PD184352, 2 μM SU5402, 3 μM CHIR99021, 10 μM Forskolin, 1,000 U / ml human LIF, 100 ng / ml FGF2, 1.74 ng / ml TGFβ1 and 1% BSA. N2B27 medium consisted of a mixture of 1:1 DMEM / F12 medium and Neurobasal medium, 0.5% v / v N-2 Supplement, 0.5% v / v B-27 Supplement, 2 mM MEM Non- Essential Amino Acid Solution, 1% v / v GlutaMAX Supplement, 0.1 mM 2-mercaptoethanol, 100 U / mL Penicillin, and 100 pg / mL Streptomycin, as previous reported.
[0156] Quantitative Reverse Transcrip tion-PCR (qRT-PCR) Analysis
[0157] Total RNA was isolated with RNeasy mini kits (Qiagen, 74106). Genomic DNAs were removed by DNase I (Qiagen, 79254) incubation. A total of 0.5 g RNAs were then reverse transcribed into cDNA using iScript reverse transcription supermix (Bio-Rad Laboratories, 170- 8891). qRT-PCR reactions were performed with SYBR Green supermix (Bimake, B21203) usingthe ABT 7500 Fast platform (Thermo Fisher Scientific). GAPDH was used as the housekeeping gene for quantification.
[0158] Embryoid Body Differentiation
[0159] To induce EB formation for in vitro differentiation demonstration, bESC lines were grown to 70-80% confluency and mainly as middle-size colonies, the cells were treated with freshly prepared 1 mg / mL collagenase for 30 min and removed from the plate by pipetting. After three washes with DMEM / F12, the cells were plated onto low-adhesive petri dishes in EB formation medium (DMEM / F12 with 20% KSR and DMEM with 10% FBS 1:1 medium supplemented with 3 μM CHIR99021 and 20 ng / ml Activin (R&D Systems, 338ACO1O)). Half of the medium was changed to DMEM with 10% FBS every other day. EBs were treated by 0.05% Trypsin (Gibco, 25200056) 5 days later and plated onto gelatin-coated plates. The cells were subjected to immunofluorescence staining after another 7 days of culture.
[0160] Neural Progenitor Cell (NPC) Differentiation
[0161] Bovine NPC direct differentiation protocol was modified based on the instruction of STEMdiff™ SMADi Neural Induction Kit (Stem Cell Technologies, 08581). Briefly, EBs were generated as mentioned above while the cells were cultured in STEMdiff™ Neural Induction Medium with SMAD inhibitors and 10 μM ROCKi for 4 days. The EBs were transferred to Matrigel coated wells and cultured in STEMdiff™ Neural Progenitor Medium for another 15 days when the cells were subjected to immuno staining.
[0162] Primordial Germ Cell-Like Cell (PGCLC) Induction
[0163] Bovine PGCLCs were induced directly from JY-bESCs following a published protocol (9). Briefly, 3.5x103JY-bESCs were seeded into each well of ultra-low attachment round-bottom 96-well plates (Corning, 7007) in GK15 medium containing GMEM, 15% (v / v) KSR, 1x sodium pyruvate, 1x NEAA, 1x β-mercaptoethanol, 1x Glutamax and 0.5x penicillin and streptomycin, supplemented with 500 ng / mL BMP4 (GIBCO, PHC9534), 500 ng / mL BMP8a (R&D Systems, 1073BP010), 1000 U / mL LIF, 100 ng / mL SCF (R&D, 255SC010), 50 ng / mL EGF (Sigma, E9644) and 10 μM ROCKi. The cells were subjected to RNA extraction and immunostaining four days later.
[0164] Immunostaining
[0165] The cells were first fixed in 4% PFA for 15 min at room temperature and treated with 0.5% Triton X-100 in PBS for 15 min membrane permeabilization. After blocking with 5% goatserum (Cell Signaling Technology, 5425S) in PBS, the cells were incubated in goat serum containing primary antibodies for 2 h at 37 °C, followed by secondary antibodies at room temperature for 1 h. Similarly, the aggregated embryos at blastocyst stage were fixed in 4% PFA for 20 min and permeabilized in 0.5% Triton X-100 for 30 min at room temperature. The embryos were blocked with goat serum and incubated with primary antibodies at 4 °C overnight and secondary antibody at room temperature for 1 h. Cells and embryos were counter- stained with DAPI and mounted on slides in Slow fade® Gold antifade reagent (Invitrogen, S36938). The slides were imaged under a Nikon AIR confocal microscope.
[0166] Primary antibodies including OCT4 (Santa Crutz, sc-9081), SOX2 (Merck Millipore, AB5603), NANOG (Invitrogen, 14-5768-80), GATA4 (Cell Signaling Technology, 36966), TUJ1 (Invitrogen, A25532), SMA (Invitrogen, A25531), SOX2 (Invitrogen, 14-9811-80), NESTIN (Abeam, ab5968-100), PAX6 (Santa Crutz, sc-81649), PRDM1 (Invitrogen, 14-5963- 82), TFAP2C (Sigma, HPA055179) and SOX17 (Origene, TA500044S), H3K27me3 (Merck Millipore, 07-449) were diluted according to the manufacturer’s instructions. Alexa Fluor 488, 594 or 647 conjugated goat anti-rabbit or goat anti-mouse secondary antibody (Cell Signaling Technology) were used in 1:1000 dilution. For cell surface marker staining, the cells were stained with NL557-conjugated TRA-1-60 (R&D Systems, NLLC4770R), SSEA-3 (R&D Systems, MAB1434) and Alexa Fluor 594 conjugated SSEA-4 (BioLegend, 330414) according to the manufacturer’s protocol.
[0167] RNA Fluorescence in situ Hybridization (FISH)
[0168] Bovine XIST probes with Quasar 570 Dye and HUWE1 probes with Quasar 670 Dye were purchased from Biosearch Technologies (SMF-1063-5 and SMF-1065-5). Cell fixation and hybridization were performed by following the manufacture’s recommended protocol.
[0169] Teratoma Assay
[0170] The JY-bESCs were treated with 10 μM ROCKi for 2 h before TrypEE digestion. After digestion and centrifugation, the cells were resuspended with 30% chilled Matrigel (Corning, 354230) in DMEM / F12 and 10 μM ROCKi. 5 x 106of JY-bESCs were injected into the hint leg of 10-week-old male NOD-SCID mice (Charles River, 394NODSCID) intramuscularly (100 pl per injection). Six to eight weeks after the injection, the teratomas were dissected and fixed in 10% formalin. Paraffin-embedded teratomas were sectioned and stained with hematoxylin and eosin.
[0171] RNA-seq and Data Analysis
[0172] Total RNA was isolated from JY-bESCs using miRNcasy Mini kit (Qiagen, 217004). The quality of total RNA was examined by Nanodrop, Agarose Gel Electrophoresis and the Aglient 2100 bioanalyzer. Ribosomal RNA was then removed by using Ribo-Zero-rRNA Removal kit (Epicentre). To prepared sequencing library, first, the mRNA was fragmented randomly by adding fragmentation buffer, then the cDNA was synthesized by using mRNA template and random hexamers primer, after which a custom second-strand synthesis buffer (Illumina), dNTPs, RNase H and DNA polymerase I were added to initiate the second-strand synthesis. Second, after a series of terminal repairs, ligation and sequencing adaptor ligation, the double-stranded cDNA library was completed through size selection and PCR enrichment. Finally, sequencing libraries were quantified by using Agilent 2100 bioanalyzer and then fed into Illumina sequencers.
[0173] The RNA-seq data analysis was conducted at usegalaxy.org. The published datasets including bMSC (1), bEPSC (2), primed bESC (3), and bovine embryos at 16-cell (10) and blastocyst (3) stages were used for comparison. Sequencing adapters and reads with low quality were trimmed using Cutadapt before mapping. The quality of reads after filtering was examined using fastQC. For mapping, bovine genomic sequence and RefSeq gene coordinate (ARS- UCD1.2 / bosTau9) were downloaded from the UCSC genome browser. All filtered reads were aligned to bovine reference genome by RNA STAR (Galaxy Version 2.7.8a) with default parameters. The number of reads per gene was counted by featureCounts (Galaxy Version 2.0.1). Differentially expressed genes between different samples were identified using default parameters in DESeq2 (Galaxy Version 2.11.40.6+galaxyl), which generated a principal component analysis plot and the heatmap of the samp le-to- sample distance matrix. The normalized counts for each sample were also used for GSEA analysis (gsea-msigdb.org), with the absolute log2(FC) > 1 values used for IPA analysis (Qiagen).
[0174] Karyotyping
[0175] Karyotyping was carried out on different bESC lines. bESCs were first incubated with 20 pg / ml Demecolcine (Sigma-Aldrich, D7385) at 37°C for 2 h, following which the cells were harvested by trypsinization. The cells were then incubated in hypotonic solution (0.56% KC1 solution) for 15 min at 37°C. After washing in the fixative solution three times (methanol / glacial acetic acid 3:1), the cells were dropped onto wet and ice-cold glass slides.Giemsa (Sigma- Aldrich, G3032) at 1 :20 dilution was applied onto the dried slides for staining. The nuclei were visualized with an Olympus microscope under a 100X oil objective lens.
[0176] Bisulfite Sequencing
[0177] For bisulfite sequencing, genomic DNAs were extracted and bisulfite converted using the EpiTeck Bisulfite Kit (Qiagen, 59104). Bovine OCT4 and NANOG proximal promoter regions were amplified using PCR primers previously reported (11), and OCT4 distal primers were designed on MethPrimer. The sequences of the primers are as follows. For OCT4 proximal promoter region primers, forward primer: 5’-GTTTGGAGAGGGGTTTTGAAGAATGTGTAG- 3’ (SEQ ID NO:1), and reverse primer: 5’-ATCCCACCCACTAACCTTAACCTCTAAC-3’ (SEQ ID NO:2). For OCT4 distal enhancer region primers, forward primer: 5’- TGTTTGGAGAATTTTATGGATAGAG-3’ (SEQ ID NO:3), and reverse primer: 5’- CCAATTAAATCATCAAACCTAACTC-3’ (SEQ ID NO:4). For NANOG proximal promoter region primers, forward primer: 5’-TAGGTGGTTATAGGAGATGTATTTTTGATT-3’ (SEQ ID NO:5), and reverse primer: 5’-TTATAAATAAAACTCAACCATACTTAACCC-3’ (SEQ ID NO:6). PCR were performed with CloneAmp HiFi PCR Premix (Takara Bio USA, 639298) and cloned using the In-Fusion HD Cloning System (Clontech, 638910) into pIRES2-DsRed vector digested by Bglll and EcoRI (New England Biolabs). Clones were picked, cultured in 6 mL LB medium with antibiotics overnight, and plasmid DNAs were extracted using a Qiaprep Miniprep Kit (Qiagen, 27106) and subjected to Sanger DNA sequencing. The results were then analyzed using the BiQ Analyzer.
[0178] In Vivo Inter- and Intra-species Chimera Assays
[0179] We first generated a bESC fluorescent line using piggyBac based PB-CAG-eGFP and pCAG-PBase plasmids. Chimeric embryos were then generated by aggregating mouse embryos with the GFP-positive bESC line as described previously (6). E2.5 mouse morulae were isolated from CD-1 females (Charles River). Zona pellucidae were removed by brief exposure to acidic Tyrode’s solution (Sigma-Aldrich, T1788) followed by three washes in KSOM embryo medium (Millipore, MR-101-D). Zona-free embryos were placed individually in micro- wells with KSOM embryo medium in an aggregation plate covered with light mineral oil (Fisher Scientific, 01211). Bovine ESCs were fed 2 h before aggregation by replacing media. Cells were washed 2x with PBS, dislodged from the plates by brief exposure to 0.05% Trypsin (Sigma, SM-2003-C) to obtain clumps of 8 to 12 cells. Two clumps of cells were then placed with a zona-free embryo inthe micro-well and co-cultivated in a 37 °C incubator with 6% CO2, 5% O2and 89% N2. After an overnight incubation, bESC-mousc embryo aggregates that did not develop into blastocyst were discarded and 90 to 92 blastocysts from each line were then transferred into pseudopregnant females for subsequent development. Embryos were harvested on E7.5 and E8.5 and fixed in 4% PFA for further analysis.
[0180] For the generation of bovine-bovine chimeric embryos, the embryos were produced by IVF as described before. Zona pellucidae were removed from Day 3 (Day O=fertilization) 8- cell stage embryos and Day 5 morulae by the treatment of 2 mg / mL Pronase for 2 min at 38.5°C followed by three washes in IVC medium. Similarly, the ZP-free embryos were individually cultured with three clumps of eight to twelve bESCs in the micro-wells at 38.5°C, 5% O2and 5% CO2until Day 7 in IVC medium supplemented with 20 ng / mL LIF, 40 ng / mL bFGF (Future Fields) and 20 ng / mL IGF-1. The aggregated bovine embryos were collected on Day 7 and 20 positive ones were shipped to TransOva Genetics. The embryos were transferred to five cows on Day 8 (Day 0=estrus) for further development. Embryos were flushed non-surgically on Day 25 for downstream analysis.
[0181] Genotyping of the Chimeric Embryos
[0182] Genomic DNA was isolated from mouse embryos or extraembryonic tissue using QIAamp DNA FFPE Tissue Kit (Qiagen, 56404). A total of 100 ng of genomic DNA was used for each PCR reaction with primers specific for mouse (forward primer: 5’- TGTGGGCAAAGAGGCTTCAT-3’ (SEQ ID NO:7), reverse primer: 5’- CAAAGCTGACTTAGCCTCAG-3’ (SEQ ID NO:8)), and bovine (forward primer: 5’- GATTGTTGATCCCACAGAAGGCAATC-3’ (SEQ ID NO:9), reverse primer: 5’- GAACTTTCAAGCAGCTGAGGCATTTA-3’ (SEQ ID NO: 10)) sequences using TikTaq Hot Start PCR Master Mix (Monte Biotech, 560001).
[0183] Immunohistochemistry (IHC)
[0184] For IHC analysis, E7.5 and E8.5 mouse chimeric embryos were isolated with their decidua from the uterus of pregnant mice. The embryos observed with obvious GFP signals were fixed in 4% paraformaldehyde and sent to Yale Pathology Tissue Services in 70% ETOH for further embedding, sectioning and IHC staining. In general, the embryos were embedded in paraffin and sectioned to 6 pm sections. Three sections per sample were made with 50 pmbetween each section. The sections were then treated with GFP antibody (Abeam, ab290). Chromogenic DAB was used as a substrate and the slides were counterstained with hematoxylin.
[0185] CRISPR / Cas9-Mediated Gene Editing in bESCs
[0186] A CRISPR-Cas9 reporter vector containing the target sequence followed by an out- of- frame sequence of dTomato gene (12) was used to test CRISPR / Cas9-mediated gene editing in bESCs. Briefly, this reporter vector was packaged into lentiviruses and introduced into the GFP-bESC line by spin infection as previously (l).The Sp-Cas9 protein was expressed and purified following the published method (13). To prepare CAS9, the Sp-Cas9 construct was transformed into Escherichia coli strain BL21 (DE3) (New England Biolabs, MA, USA) and induced by 1 mM isopropylb-D-1 -thiogalactopyranoside at optical density of 0.6-0.8. After overnight incubation at 23°C, cells were centrifuged and resuspended in xTractor Buffer containing DNase I, lysozyme solution, and Protease Inhibitor Cocktail (Takara Bio USA, Inc., CA). The supernatant of the sonicated cells was incubated with equilibrated TALON Metal Affinity Resin (Takara Bio USA, Inc., CA, USA) for 20 min on ice. The proteins were eluted from resin with the elution buffer (pH 7.0, 150 mM imidazole, 50 mM NaH2PO4, and 300 mM NaCl). The eluted proteins were concentrated and with buffer exchanged to phosphate-buffered saline (pH 7.4) using Protein Concentrator PES, 3K MWCO (Pierce Biotechnology, PA, USA). The purified Cas9 protein (50 pmol) was used to form the ribonucleoproteins (RNP) complex with sgRNA (250 pmol) in 37°C for 10 min. Then the RNP was transfected into 5x105bESCs with CRISPR-Cas9 reporter by electroporation. The fluorescence was observed 48 h after the transduction.
[0187] Electroporation
[0188] Bovine ESCs (5x105) in 180 μL TiF2 medium were mixed with 20 μL RNP (50 pmol Cas9 and 250 pmol sgRNA) or 10 pg PB-CAG-eGFP and pCAG-PBase plasmids (Addgene) in 20 μL Opti-MEM and added into 4 mm gene pulser cuvettes (total volume 200 μL). The voltage and capacitance used for electroporation were 200V and 500 pF. After electroporation, the cells were left in cuvette for 30 s and transferred into culture medium.
[0189] Statistics AnalysisOne way-ANOVA with Tukey's multiple comparison test or Student's t-test was used for data analysis. The figures were presented as mean ± standard deviation (sd). A p-value < 0.05(*) or 0.01(**) was considered statistically significant. All data were analyzed with SPSS.
[0190] The JY-bESCs are pluripotent stem cells, which are derived from bovine pre- implantation embryos. They exhibit long-term propagation and in vivo and in vitro differentiation abilities. Due to their origins and properties, the cells can be used to study gene regulation and development / differentiation in early bovine embryos. With the single-cell colonization ability and long-term propagation ability, the JY-bESCs are ideal for gene editing especially multi-genes editing to study gene functions and to produce genetically engineered animals by nuclear transfer, germ-line chimera production, tetrapioid complementation or artificial gametes induction to improve production efficiency, disease-resistance, and quality / safety of animal products. The JY-bESCs are also good candidates for pharmaceutical protein and cultivated meat production due to their large-scale expansion and differentiation ability without transgenes. The direct differentiation ability, such as the NPC conversion, also allows the establishment of disease models for mechanism study and drug screening. The PGC direct induction from JY-bESCs makes the in vitro produced gametes possible for infertility treatment and faster molecular breeding. The high interspecies chimeric contribution of JY- bESCs would foster to generate biomedical models for human regenerative medicine and zoonotic disease prevention.
[0191] Example 3: Preparation of TiF2 and TiF3 Medium
[0192] TiF2 medium is prepared by combining mTeSR-plus media (STEMCELL Technologies, 100-0276) supplemented with 2.5 μM IWR1 (AOBIOUS, AOB33702), 3.3 μM iDOT1L (AOBIOUS, AOB1922), 0.8 μM PD184352 (ApexBio, A1792), 2 μM SU5402 (ApexBio, A3843), 3 μM CHIR99021 (AOBIOUS, AOB3866), 10 μM Forskolin (AOBIOUS, AOB6380), and 1,000 U / ml human LIF (R&D Systems, 7734LF025), with the presence of 10 μM ROCKi (AOBIOUS, AOB3877) when passaging the cells.
[0193] TiF3 medium is prepared by combining N2B27 media supplemented with 2.5 μM IWR1 (AOBIOUS, AOB33702), 3.3 μM iDOT1L (AOBIOUS, AOB1922), 0.8 μM PD184352 (ApexBio, A1792), 2 μM SU5402 (ApexBio, A3843), 3 μM CHIR99021 (AOBIOUS, AOB3866), 10 μM Forskolin (AOBIOUS, AOB6380), 1,000 U / ml human LIF (R&D Systems,7734LF025), 1 % BSA, 100 ng / ml bFGF and 1 .74 ng / ml TGF β1, with the presence of 10 μM ROCKi (AOBIOUS, AOB3877) when passaging the cells.
[0194] Example 4: Derivation and Characterization of bESCs from Bovine In Vitro Blastocysts
[0195] Previously, established bovine induced pluripotent stem cells (biPSCs) (described in WO 2023 / 122571) in mTeSR plus medium supplemented with H3K79 methyltransferase inhibitor iDOT1L were established tankyrase inhibitor IWR1, MEK inhibitor PD0325901, glycogen synthase inhibitor CHIR99021 (2i) / LIF, and PKA agonist forskolin (TiF medium). Replacing PD0325901 with mild MEK / ERK inhibitors (PD184352 and SU5402), which supported the ground state mouse ESC capable of germline transmission (referred to as the TiF2 medium herein) resulted in thicker biPSC colonies and improved pluripotent gene expression (FIGs. 6 A and 6B).
[0196] The applicability of TiF2 medium for bESC derivation was tested. By culturing zona pellucida (ZP)-free bovine blastocysts in TiF2 medium on mitomycin C-treated mouse embryonic fibroblasts (MEF), we successfully derived 10 bESC lines (“JY-bESC”) from 15 in vitro fertilized embryos that included 3 female and 7 male lines (FIG. 1A). JY-bESCs exhibited round, compact and dome-shaped colonies (FIG. IB) and were SSEA4 positive (FIG. 1C). The doubling time of the established JY-bESC lines was 19.1+0.8 h (FIG. ID), faster than biPSCs (1). JY-bESCs maintained normal karyotype even at high passages (FIG. IE) and were stably propagated by single cell colonization for over 80 times. Gene-editing by using CRISPR / Cas9 in JY-bESCs was achieved with a 1.0% success rate (FIGs. 6C and 6D).
[0197] JY-bESCs showed robust expression of pluripotency-related genes (OCT4 [a.k.a. POU5F1], SOX2, NANOG, E-CADHERIN [a.k.a. CDH1], LIN28B, ESRRB and REX]) across all passages examined (FIGS. IF, 1G and 6F). They were positive for alkaline phosphatase (AP) (FIG. 1H) and ESC surface markers SSEA3, SSEA4 and TRA1-60 (FIG. 1G and 6F). Bisulfite sequencing revealed demethylation in the OCT4 and NANOG proximal promoters and partial demethylation in the distal enhancer region of OCT4 compared to bovine mesenchymal stem cells (bMSCs) (FIG. II). After the removal of growth factors, JY-bESCs successfully formed embryoid bodies (EBs) expressing markers for ectoderm, mesoderm, and endoderm (FIGs. 1J, 6E and 6G). When injected into NOD-SCID mice, JY-bESCs formed teratomas with the structures of three germ layers within four to six weeks (FIGs. 1K and 6H). Together, the typical ESC morphology, highly expressed pluripotency-related genes and three-germ layer differentiation both in vitro andin vivo demonstrate successful derivation of bESCs from bovine blastocysts under the TiF2 culture condition.
[0198] Comparative Transcriptomic Analysis of Bovine PSCs
[0199] To investigate the molecular signatures among different bovine PSCs, transcriptomic analysis was conducted on JY-bESCs and previously reported bEPSCs (2), bpESC (3) and biPSCs(4) (Table A).
[0200] Using principal component analysis (PCA), it was found that six lines of JY-bESCs were clustered between bEPSCs and biPSCs, suggesting their distinct cellular state (FIG. 2A). Next, 643, 1,787, and 2,065 were identified as upregulated and 639, 459, and 528 downregulated genes in JY-bESCs relative to bEPSCs, biPSCs and bpESCs, respectively (Table B).
[0201] Focusing on JY-bESCs, bpESCs and biPSCs, specifically, 451 genes were uniquely expressed in JY-bESCs, 275 in biPSCs, and 415 in bpESCs (FIG. 2B). Enriched GO terms in JY- bESCs included integrin, activin, and Nodal signaling pathways (FIG. 2B). KEGG pathway analysis highlighted ribosome biosynthesis, RAP1, and TGF-beta signaling pathways (Table C).
[0202] For bpESCs, enriched GO terms and KEGG pathways included cell dedifferentiation, negative regulation of canonical WNT pathways, MAPK signaling, and FoxO pathways (FIG. 2B and Table C). In addition, biPSCs showed enrichment in embryonic organization and fate determination GO terms, with KEGG analysis revealing Hippo signaling pathways and pluripotency regulation (FIG. 2B and Table C). Notably, biPSCs also exhibited lower expression of NANOG and higher trophectoderm marker CDX2 compared to other cells (FIGs. 2B and 2C).
[0203] To define the pluripotent state of lY-bESCs, various stages of bovine embryonic development were compared, including pre- and post-implantation embryos. Specifically, different PSCs were compared with bovine dissected inner cell mass (ICM) from Day 7 blastocysts, epithelial radially symmetric epiblast (ERSE) from Day 14 embryos, and anterior to posterior epiblast (APE) from Day 17 embryos (5).The PCA analysis revealed that the bovine PSCs were separated from the bovine embryo samples along PC1 / PC2 (FIG. 7A) and the primed state bpESCs exhibit a closer resemblance to APE while the naive state biPSCs align closer with ICM along PC2 / PC3 (FIG. 2A). Notably, JY-bESCs were positioned intermediately between ICM and APE stages along PC2 / PC3, indicating their transitional state (FIG. 2A). Known markers representing different pluripotency states in these bovine PSCs (FIG. 2C) were examined. These markers were defined in mice and showed species-specific expressions across expanded, naive, formative, and primed PSCs in mice (FIG. 7B) and humans (FIG. 7C). Among bovine PSCs, biPSCs had high expression of naive pluripotency markers (ESRRB, KLF4 / 2, ZFP42, XR5A2) and upregulated primed markers (GATA6, PAX3) (FIG. 2C). JY-bESCs predominantly expressed formative markers (15 out of 21) such as CLDN6 / 7, DNMT3B, ESRP1, GRHL2, and LIN28B. while also showing expression of expanded (LIN28A), naive (STAT3, TFCP2L1), and primed markers (EOMES, RUNX1 ) (FIG. 2C). Bovine primed ESCs were enriched in primed markers and showed scattered gene enrichment across other pluripotency panels (TET1 / 2, JAM2, FGF5, POU3F1, FOXA2). bEPSCs had one enriched expanded marker (AIRE) and elevated expression of some formative (CLDN6, UTF1) and primed markers (EOMES) (FIG. 2C). The predominant expression of formative markers in JY-bESCs indicated a formative pluripotent status for JY-bESCs compared to other reported bovine PSCs. The cells were compared with bovine somatic cells (bovine mesenchymal stem cells, bMSCs) and found that the bMSCs exhibited enrichment in differentiation genes (GDF6, SST, LAMAS, HAND1, DKK1), whereas the top differentially expressed genes (DEGs) in JY-bESCs were prominently associated with pluripotency (LIN28A,OTX2, OCT4. NANOG) (FIG. ID). This finding confirms and emphasizes the pluripotency of JY- bESCs.
[0204] Cross-species Analysis for Bovine-specific Features
[0205] To further identify the pluripotency status of bovine PSCs, the transcriptomic differences among PSCs of the human, mouse and bovine and their blastocysts (Table A) were compared. In general, 2D PCA (FIG. 2D) for all three species revealed a clear cell trajectory based on pluripotency states from expanded / extended, naive, formative, to primed PSCs. Interestingly, mouse expanded / extended PSCs (EPSC) are next to naive PSCs, while human and bovine EPSCs are closer to formative PSCs, indicating similarity between human and bovine PSCs compared to mouse. Further projection of JY-bESC to humans or mice PSCs revealed JY-bESCs to be closest to human formative PSCs (hFSCs, FIG. 2E), and between mouse mFSCs and primed PSCs (mpESC, FIG. 8A).
[0206] Intriguingly, bovine, mouse, and human PSCs and blastocysts showed clear species- specific separation along PC3 of the 3D PCA (FIG. 2F). KEGG analysis on the top 2,000 PC3 contributors revealed significant enrichment in metabolic pathways, including carbon metabolism, N-glycan biosynthesis, reactive oxygen species, purine synthesis, and biosynthesis of cofactors (FIGs. 9A-9F). Notably, genes that affect carbon metabolism including glycolysis (TPI1, PGAM1, ALDOA) and TCA cycle (ACSS1, GLUD1, AMT, SDHA) displayed species- specific expression patterns, with bovine showing the highest expression for PGAM1 and GLUD1 and comparable expression as mice for the other genes, and with humans having the lowest expression for most of these genes except for TPI1 (FIG. 9B). Additionally, bovine early embryonic development showed a significant shift of glycolysis intermediates towards lipid metabolism, with the lowest expression of TPI1 (FIG. 9B) but greatest expression of GPD1 - key gene for cytoplasmic glycerolipid synthesis in bovine compared with humans and mice, and the lowest expression of GPD2 which mediates the reversible interaction of GPD1 in mitochondria (FIG. 9G). Interestingly, TP / 1 and GPD1 expression is much higher in bovine PSCs compared to embryos, particularly for TPI1 in JY-bESCs (FIG. 9G-9H). The distinct expression pattern of genes related to carbon metabolism indicate species-specific variations in mitochondria carbon metabolic rates among human, mouse, and bovine early embryos and PSCs.
[0207] To further define species-specific pluripotency, JY-bESCs were compared to human and mouse formative (hFSCs and mFSCs, FIG. 8B and Table D) or primed PSCs (hpESC and mpESC, FIG.8C and Table E).Table D: DEG numbers (Up-regulated and Down-regulated) in comparisons of JY-bESC vs. hFormative_Kinoshita, JY-bESC vs. mFormative_Kinoshita, and hFormative_Kinoshita vs. mFormative_KinoshitaTable E: GO terms enriched by genes uniquely expressed in hFSCs, JY-bESCs, and mFSCs
[0208] 597, 804 and 431 genes were identified as uniquely expressed in hFSCs, JY-bESCs, and mFSCs (FIG. 8B), while 621, 606, 464 genes were specifically enriched in hpESC, JY-bESC and mpESCs, respectively (FIG. 8C). Comparing JY-bESCs to formative PSCs revealed GO term enrichment in integrin signaling pathway for JY-bESCs and protein glycosylation and WNT signaling pathway for hFSCs and mFSCs, respectively (FIG. 8B and Table F).Table F: DEG numbers (Up-regulated and Down-regulated) in comparisons of JY-bESC vs. hpESC_Bi, JY-bESC vs. mpESC_Liu, and hpESC_Bi vs. mpESC_Liu.
[0209] Comparing JY-bESCs to primed PSCs unveiled enrichment in species-specific GO terms: extracellular matrix organization for JY-bESCs, regulation of neuron projectiondevelopment for hpESCs, and ribose phosphate metabolic process for mpESCs (FIG. 8C and Table G).Table G: Table SIG. GO terms enriched by genes uniquely expressed in hpESCs, JY-bESCs, and mpESCs
[0210] Analyzing blastocysts in three species revealed 984 messages that were detected in only in the bovine embryos, with 75 genes overlapping with JY-bESC uniquely expressed genes amongFSCs (FTG. 8D). These bovine specifically expressed genes were enriched in KEGG pathways including RAP1, VEGF, and MAPK signaling pathways (Table H).Table H: KEGG pathways enriched by 75 genes shared between the JY-bESC uniquely expressed genes and bovine-specific embryonic genes.[02111 The species-specific transcriptomic features we identified in bovine, human, and mouse PSCs and blastocysts provide insights into unique biological processes underlying early development of bovine PSC and embryos.
[0212] Dosage Compensation of the X Chromosome in Bovine Female ESCs
[0213] Using RNA-FISH and immunostaining, we found that the female JY-bESC Line (JY- bESC-8, FIGs. 10A and 10B) was enriched in H3K27me3, and expressed XIST and a single copy of the X-linked gene HUWE1, suggesting X-chromosome inactivation (XaXi) (FIGs. 2G and 2H). After another six passages, the X chromosome status remained unchanged (FIGs. 2G, 2H and 21). RNA-seq analysis of six JY-bESC lines (one female and five male lines) confirmed the XIST expression pattern (FIG. 10C) and complete X chromosome dosage compensation (FIG. 2J). To assess X chromosome inactivation, we further analyzed the X:A allelic ratio for bi-allelic and monoallelic single-nucleotide polymorphisms (SNPs) in the JY-bESC-8 line (FIG. 2K). Consistent with RNA-FISH results, JY-bESC-8 showed strong monoallelic tendency (X:A allelic ratio higher than 2) and a low X:A ratio for bi-allelic genes, further supporting the establishment of XaXi status in female JY-bESCs.
[0214] Direct Differentiation of bESCs to Neural Progenitor Cells and Primordial Germ Cell-Like Cells
[0215] The direct differentiation of bESCs such as the induction of artificial gametes and neural progenitor cells (NPCs) is critical for cell-based models to study bovine spongiform encephalopathy and perform drug screening. Also, a key feature of formative human and mouse PSCs is direct in vitro differentiation to PGCLCs. By blocking TGF-β and BMP-dependent SMAD signaling, bovine NPCs were induced within two passages (19 days), confirmed by immuno staining for NPC markers (SOX2, NESTIN, and PAX6) and elevated NPC marker gene expression (FIGs. 3A-C). Additionally, treatment with germ cell stimulator BMP4 for four days increased expression of PGC-related genes and BMP8A further strengthened PGCLC induction(FIGs. 3D and 3E) as demonstrated by positive staining of PGC markers (TFAP2C, PRDM1 , and S0X17) (FIGs. 3F and 61). Moreover, the PRDM1+ cells exhibited co-cxprcssion with H3K27mc3, while showing minimal H3K9me2 staining (FIG. 3G). This staining pattern aligns well with previous reports on PGCs. The triple positive ratio of TFAP2C, PRDM1 and SOX17 in bovine induced PGCLC is 21.5 ± 2.8%, which is comparable to the rates of PGCLC induction of human and mouse formative PSCs. Therefore, the elevated and co-expression of NPC and PGC markers indicated efficient direct differentiation of JY-bESCs into NPC and PGCLC in vitro.
[0216] Bovine ESCs contributed to the Embryonic and Extra-embryonic Tissues of Chimeras
[0217] To determine the in vivo developmental potential of JY-bESCs, GFP-expressing (GFP+) JY-bESCs were established and aggregated with mouse early morulae for the creation of interspecies chimeras (1, 6). GFP signals were observed in the mouse blastocysts 24 hours after aggregation (FIG. 4A) and were verified by immunofluorescence staining (FIG. 4B), which showed that GFP+ cells were co- stained with markers of both ICM, Sox2, and trophectoderm (TE), Cdx2. Chimeric blastocysts were transferred into pseudopregnant females and retrieved on E7.5 and E8.5. Two out of eight E7.5 and three out of 44 E8.5 mouse embryos contained obvious GFP signals (FIG. 11 A). GFP signals were further detected by immunohistochemistry (IHC) with serial sections in caudal extremity, midgut, notochord, somite, and amnion of E7.5 chimeric embryos (FIGs. 4C and 1 IB). PCR analysis also confirmed the presence of bovine DNA in both embryonic and extraembryonic tissues of the remaining chimeric embryos at high frequency (33.3% embryo proper and 66.7% decidua of E7.5 and 82.8% embryo proper and 38.1% decidua of E8.5 embryos, respectively) (FIGs. 4D and 11C), in accordance with the blastocyst staining result. The detection of bovine cells in various tissues of mouse-bovine chimeras demonstrated the successful contribution of JY-bESCs to both embryonic and extraembryonic tissues in interspecies chimeric embryos.
[0218] To date, extraembryonic differentiation has only been reported in bovine expanded PSCs (2). To this end, GFP+ JY-bESCs were aggregated with bovine embryos at the 8-cell and morula stages and further cultured them in vitro for 48 or 96 hours, respectively. GFP+ cells were identified in both ICM and TE of the bovine blastocysts (FIGs. 4E, 4F and HD). To investigate the in vivo development potential of the aggregated bovine chimeric embryos, 20 Day 8 GFP+ embryos were transferred to five recipient cows and five embryos from four recipients on Day 25(Day 0 = estrus) were retrieved (FIG. 1 IE). All embryos (100%) showed strong GFP signals in their extraembryonic tissues, and two out of five embryos had visible clusters of GFP+ cells in embryonic discs by using a fluorescent microscope with 4X magnification (FIG. 4G). FACS analysis confirmed 1.8% of the total dissociated cells from the two embryos (42,358 out of 2.2 x 106) were GFP+ (FIG. 1 IF).
[0219] Single Cell Transcrip tome Profiling of JY-bESC Derived Bovine Chimeras
[0220] Using lOx Genomics Chromium platform for scRNA-seq, 3,354 GFP+ JY-bESCs- derived cells and 1,083 GFP- host cells were examined from the two Day 25 embryonic disks after spiking-in cells from one extraembryonic sample. 9 clusters were identified, representing progenitors of the nerves system (Clusters 0, 4 and 5), cardiomyocytes (Cluster 1) and erythroid progenitor cells (Cluster 2) (FIGs. 4H, 41, 12A, 12B and Table I).Table I: Gene markers and references used for bovine cell type annotating.
[0221] Extraembryonic mesoderm (Cluster 3) of the hypoblast origin and trophectoderm cells (Clusters 6-8) were also found, presumably from the spiked-in extraembryonic cells, which contained strong GFP signals (FIGs. 4H, 41, 12A, 12B and Table I). GFP+ and GFP- cells overlapped in all the identified cell types (FIG. 41), indicating similar developmental trajectory by JY-bESCs and cells of the host embryos. 33 GFP+ and 8 GFP- cells were found that expressed atleast three PGC-specific markers (OCT4, DPPA3, TFAP2C, PRDM1 , SOX15, KIT, ITGA6, PDPN, EPCAM or ALPL) termed “putative PGCs” (Tables J and K).Table J: The expression level of PGC markers in putative migrating PGCsTable K: Distribution of putative migrating PGC numbers with at least three PGC-markers expression
[0222] Certain PGC markers that were barely shown in the scRNA-seq results, such as OCT4, NANOG, NANOS3, and SOX17 were also detected in the scRNA-seq library through PCR with strong signals (FIG. 12C), suggesting the existence of PGCs among the cell population. Together, the different tissues or cell types identified in the GFP+ Day 25 bovine chimeric embryos demonstrate, for the first time, the efficient incorporation of formative bESC into bovine embryonic and extraembryonic tissues in vivo.
[0223] Chemical-Defined Medium Sustains the Pluripotency of Bovine ESCs
[0224] To determine the essential components in the TiF2 medium, supplemented small molecules and growth factors were systematically clciminatcd from TiF2 and screened the morphology of bESCs. Remarkably, within just three days of culture, cells began either differentiating or succumbing to cell death (FIG. 5A), suggesting all the components are indispensable for JY-bESC culture. The basal medium of TiF2, mTeSR plus, is a commercially available product with a complex formulation. Thus, it was endeavored to discover a chemically defined medium capable of sustaining the growth and pluripotency of bESCs. The investigation led to replacing mTeSR plus with N2B27 basal medium (7) supplemented with 1% BSA, alongside equal amounts of FGF2 and TGFβ1 in mTeSR medium (8) (designated as TiF3 medium). Notably, JY-bESCs maintained robust colony morphology and exhibited comparable expression levels of pluripotency genes for a minimum of eight passages (FIGs. 5B and 5C) in TiF3 medium. Furthermore, these cells demonstrated the capacity to spontaneously differentiate into all three germ layers in vitro (FIG. 5D). These results highlight the efficacy of TiF3 medium as a simplified yet effective alternative to mTeSR plus based TiF2 for maintaining bESC pluripotency.
[0225] Derivation of bESCs from bovine early embryos has been challenging for decades. The previously reported bESC lines showed limited propagation ability, refractory to single-cell colonization, confined pluripotent gene expression, and restricted differentiation capacity. While some progress has been made in recent years with primed bESCs cultured on feeders and feeder- free substrates, they lacked the demonstration of chimera formation. Similarly, newly reported bovine EPSCs (2) showed limited interspecies chimera capability. Furthermore, unlike mouse naive PSCs, which are restricted from trophectoderm differentiation, the extraembryonic plasticity of human epiblast prior to implantation has not been reported in other species. Here, successfully derived JY-bESCs in a TiF2 medium is described, resulting in defined colony morphology, high level expression of pluripotent genes, and in vitro and in vivo differentiation ability into three germ-layers. Notably, JY-bESCs demonstrated high rates of chimera formation to both embryonic and extraembryonic tissues in both interspecies (bovine-mouse) and intraspecies (bovine-bovine) chimeric embryos. Moreover, JY-bESCs exhibited species-specific formative transcriptomic profiles and could be directly differentiated into both NPCs and PGCLCs in vitro. Inter- and intraspecies chimerism further demonstrated the development potential of JY-bESCs to both embryonic and extraembryonic lineages. Taken together, JY-ESCs represent a significantadvancement in extending the extraembryonic differentiation plasticity of human naive ESCs to formative bovine PSCs, offering great promises for bioengineering and development studies.
[0226] The following terms are used to describe the invention of the present disclosure. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.
[0227] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are well known and commonly used in the ail. In case of conflict, the present disclosure, including definitions, will control. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the embodiments and aspects described herein.
[0228] As used herein, the terms “amino acid,” “nucleotide,” “polynucleotide,” “vector,” “polypeptide,” and “protein” have their common meanings as would be understood by a biochemist of ordinary skill in the art. Standard single letter nucleotides (A, C, G, T, U) and standard single letter amino acids (A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y) are used herein.
[0229] Compounds and materials are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. The following terms are used to describe the invention of the present disclosure. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.
[0230] The use of the terms “a” and “an” and “the” and similar referents (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. By way of example, "an element" means one element or more than one element.
[0231] As used herein, the term “substantially” means to a great or significant extent, but not completely.
[0232] It should also be understood that, in certain methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited unless the context indicates otherwise. Furthermore, the terms first, second, etc., as used herein are not meant to denote any particular ordering, but simply for convenience to denote a plurality of, for example, layers.
[0233] The terms “comprising”, “having”, “including”, and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted.
[0234] The terms “about” or “approximately,” as used herein, is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within ± 10% or 5% of the stated value. Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All ranges disclosed herein include both end points as discrete values as well as all integers and fractions specified within the range. For example, a range of 0.1-2.0 includes 0.1, 0.2, 0.3, 0.4 . . . 2.0. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.The use of any and all examples, or exemplary language (e.g., “such as”), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non- claimed element as essential to the practice of the invention as used herein.
[0235] The phrase "and / or," as used herein in the specification and in the claims, should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with "and / or" should be construed in the same fashion, i.e., "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to "A and / or B", when used in conjunction with open-ended language such as "comprising" can refer, in one embodiment, to Aonly (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
[0236] As used herein in the specification and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of’ or "exactly one of," or, when used in the claims, "consisting of," will refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of."
[0237] As used herein in the specification and in the claims, the phrase "at least one," in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified. Thus, as a nonlimiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently "at least one of A and / or B") can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
[0238] The phrase "one or more," as used herein, means at least one, and thus includes individual components as well as mixtures / combinations of the listed components in any combination.
[0239] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients and / or reaction conditions are to be understood as beingmodified in all instances by the term "about," meaning within 10% of the indicated number (e.g., "about 10%" means 9%- 11% and "about 2%" means 1.8%-2.2%).
[0240] All percentages and ratios are calculated by weight unless otherwise indicated. All percentages are calculated based on the total composition unless otherwise indicated. Generally, unless otherwise expressly stated herein, "weight" or "amount" as used herein with respect to the percent amount of an ingredient refers to the amount of the raw material comprising the ingredient, wherein the raw material may be described herein to comprise less than and up to 100% activity of the ingredient. Therefore, weight percent of an active in a composition is represented as the amount of raw material containing the active that is used and may or may not reflect the final percentage of the active, wherein the final percentage of the active is dependent on the weight percent of active in the raw material.
[0241] All ranges and amounts given herein are intended to include subranges and amounts using any disclosed point as an end point. Thus, a range of "1% to 10%, such as 2% to 8%, such as 3% to 5%," is intended to encompass ranges of "1% to 8%," "1% to 5%," "2% to 10%, " and so on. All numbers, amounts, ranges, etc., are intended to be modified by the term "about," whether or not so expressly stated. Similarly, a range given of "about 1% to 10%" is intended to have the term "about" modifying both the 1% and the 10% endpoints. Further, it is understood that when an amount of a component is given, it is intended to signify the amount of the active material unless otherwise specifically stated.
[0242] As used herein, the term “administering” means the actual physical introduction of a composition into or onto (as appropriate) a subject, a host, or cell. Any and all methods of introducing the composition into the subject, host or cell are contemplated according to the invention; the method is not dependent on any particular means of introduction and is not to be so construed. Means of introduction are well-known to those skilled in the art, and also are exemplified herein. “Providing” means giving, administering, selling, distributing, transferring (for profit or not), manufacturing, compounding, or dispensing.
[0243] As used herein, “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0244] Furthermore, the disclosure encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from oneor more of the listed claims are introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Where elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group.
[0245] A significant change is any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student’s T-test, where p < 0.05.
[0246] All statements herein reciting principles, aspects, and embodiments of the disclosure, as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents as well as equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure.
[0247] Various other components may be included and called upon for providing for aspects of the teachings herein. For example, additional materials, combinations of materials and / or omission of materials may be used to provide for added embodiments that are within the scope of the teachings herein. Adequacy of any particular element for practice of the teachings herein is to be judged from the perspective of a designer, manufacturer, seller, user, system operator or other similarly interested party, and such limitations are to be perceived according to the standards of the interested party.
[0248] In the disclosure hereof any element expressed as a means for performing a specified function is intended to encompass any way of performing that function including, for example, a) a combination of circuit elements and associated hardware which perform that function or b) software in any form, including, therefore, firmware, microcode or the like as set forth herein, combined with appropriate circuitry for executing that software to perform the function. Applicants thus regard any means which can provide those functionalities as equivalent to those shown herein. No functional language used in claims appended herein is to be construed as invoking 35 U.S.C. § 112(∫) interpretations as “means-plus-function” language unless specifically expressed as such by use of the words “means for” or “steps for” within the respective claim.
[0249] When introducing elements of the present invention or the embodiment(s) thereof, the articles “a,” “an,” and “the” arc intended to mean that there are one or more of the elements.Similarly, the adjective “another,” when used to introduce an element, is intended to mean one ormore elements. The terms “including” and “having” are intended to be inclusive such that there may be additional elements other than the listed elements. The term “exemplary” is not intended to be construed as a superlative example but merely one of many possible examples.
[0250] While the invention has been described with reference to an exemplary embodiment, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims. Any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.Incorporation by Reference
[0251] All U.S. and PCT patent publications and U.S. patents mentioned herein are hereby incorporated by reference in their entirety as if each individual patent publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.Other Embodiments
[0252] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above Description, but rather is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various changes and modifications to this description may be made without departing from the spirit or scope of the present invention, as defined in the following claims.References:1. Y. Su et al., Establishment of Bovine-Induced Pluripotent Stem Cells. International journal of molecular sciences 22, 10489 (2021).L. Zhao et al. , Establishment of bovine expanded potential stem cells. Proc Natl Acad Sci U S A 118 (2021). Y. S. Bogliotti et al., Efficient derivation of stable primed pluripotent embryonic stem cells from bovine blastocysts. Proc Natl Acad Sci U SA 115, 2090-2095 (2018). V. V. Pillai et al., Efficient induction and sustenance of pluripotent stem cells from bovine somatic cells. Biology open 10, bio058756 (2021). A. S. Bernardo et cd., Mammalian embryo comparison identifies novel pluripotency genes associated with the naive or primed state. Biology open 7, bio033282 (2018). R. Behringer, M. Gertsenstein, K. V. Nagy, A. Nagy, Manipulating the mouse embryo: a laboratory manual (Cold Spring Harbor Laboratory Press, 2014). Q.-L. Ying et al., The ground state of embryonic stem cell self-renewal. Nature 453, 519- 523 (2008). T. E. Ludwig et al., Feeder-independent culture of human embryonic stem cells. Nature methods 3, 637-646 (2006). K. Hayashi, M. Saitou, Generation of eggs from mouse embryonic stem cells and induced pluripotent stem cells. Nature protocols 8, 1513-1524 (2013). A. Graf et al., Fine mapping of genome activation in bovine embryos by RNA sequencing. Proceedings of the National Academy of Sciences 111, 4139-4144 (2014). H. Cao et al. , Characterization of bovine induced pluripotent stem cells by lentiviral transduction of reprogramming factor fusion proteins. Int J Biol Sci 8, 498-511 (2012). D. S. D’Astolfo et al., Efficient intracellular delivery of native proteins. Cell 161, 674- 690 (2015). J. Zhu, Y. Su, Y. Tang, Disrupting ACE2 Dimerization Mitigates the Infection by SARS- CoV-2 Pseudovirus. Frontiers in Virology 2 (2022).
Claims
CLAIMSWhat is claimed is:
1. A composition to grow a cell line, the composition comprising: a cell culture medium; and a supplement comprising: a Wingless / Integrated (WNT) inhibitor; a histone methyltransferase DOT1L inhibitor (iDOT1L); an adenyl cyclase activator; a Mitogen-activated protein kinase kinases 1 and 2 (MEK1 / 2) inhibitor; a fibroblast growth factor receptor (FGFR) inhibitor; a glycogen synthase kinase (GSK-3) inhibitor; and a leukemia inhibitory factor (LIF), wherein the composition maintains pluripotency and self-renew capacity of the cell line.
2. The composition of claim 1, wherein the supplement further comprises: bovine serum albumin (BSA); a basic fibroblast growth factor (bFGF); and a transforming growth factor β1 (TGF β1).
3. The composition of claim 1, wherein the culture medium is mTeSR-plus or N2B27.
4. The composition of claim 3, wherein the culture medium is N2B27 and the supplement further comprises: bovine serum albumin (BSA); a basic fibroblast growth factor (bFGF); and a transforming growth factor β1 (TGF β1).
5. The composition of claim 1, wherein the composition comprises at least 99% of the cell culture medium and about 1% of the supplement.
6. The composition of claim 1, wherein the supplement comprises:from about 0.1 μM to about 25 μM of the WNT inhibitor; from about 0.1 μM to about 25 μM of the histone mcthyltransfcrasc DOT1L inhibitor; from about 0.1 μM to about 10 μM of the MEK1 / 2 inhibitor; about 0.1 μM to about 10 μM of the FGFR inhibitor; from about 0.5 μM to about 10 μM of the GSK-3 inhibitor; from about 1 μM to about 50 μM of the adenyl cyclase activator; and about 100 U / ml to about 5000 U / ml of LIF.
7. The composition of claim 2, wherein the supplement comprises: from about 0.01 to about 5% (v / v) of BSA; from about 10 to about 500 ng / ml of bFGF; and from about 0.1 to about 5 ng / ml of TGF β1.
8. The composition of claim 6, wherein: the WNT inhibitor is IWR1; the histone methyltransferase DOT1L inhibitor is EPZ004777; the adenyl cyclase activator is forskolin; the MEK1 / 2 inhibitor is PD 184352; the FGFR inhibitor is SU5402; the GSK-3 inhibitor is CHIR99021; the LIF is a human LIF or a bovine LIF;9. The composition of claim 7, wherein the bFGF is a human bFGF or a bovine bFGF; and the TGF β1 is a human TGF β1 or a bovine TGF β1.
10. The composition of claim 8, wherein: the IWR1 is present in an amount of about 2.5 μM; the EPZ004777 is present in an amount of about 3.3 μM; the forskolin is present in an amount of about 10 μM the PD 184352 is present in an amount of about 0.8 μM;the SU5402 is present in an amount of about 2 μM; the CHIR99021 is present in an amount of about 3 μM; and the human LIF or bovine LIF is present in an amount of 1000 U / mL.
11. The composition of claim 9, wherein:BSA is present in an amount of about 1% (v / v); the human bFGF or bovine bFGF is present in an amount of about 100 ng / mL; and the human TGF β1 or bovine TGF β1 is present in an amount of about 1.74 ng / mL.
12. A method of producing stem cells, the method comprising the steps of: a) providing bovine pre-implantation embryos; b) treating the bovine pre-implantation embryos with an enzyme to remove the zone pellucida; c) culturing treated bovine pre-implantation embryos with a composition to form a culture, the composition comprising: i) a cell culture medium; and ii) a supplement comprising: a Wingless / Integrated (WNT) inhibitor; a histone methyltransferase DOT1L inhibitor (iDOT1L); an adenyl cyclase activator; a Mitogen-activated protein kinase kinases 1 and 2 (MEK1 / 2) inhibitor; a fibroblast growth factor receptor (FGFR) inhibitor; a glycogen synthase kinase (GSK-3) inhibitor; a leukemia inhibitory factor (LIF); bovine serum albumin (BSA); a basic fibroblast growth factor (bFGF); and a transforming growth factor β1 (TGF β1); and d) harvesting stem cells resulting from the culture.
13. The method of claim 12, wherein the supplement further comprises:bovine serum albumin (BSA); a basic fibroblast growth factor (bFGF); and a transforming growth factor β1 (TGF β1).
14. The method of claim 12, wherein the method is used to grow a bovine embryonic stem cell line (bESC).
15. The method of claim 12, wherein the enzyme is a pronase, a hyaluronidase, an acrosin or any combinations thereof.
16. The method of claim 12, wherein the culture medium is a serum free culture medium for culturing stem cell lines.
17. The method of claim 16, wherein the culture medium is mTeSR-plus or N2B27.
18. The method of claim 12, wherein the composition comprises at least 99% of the cell culture medium and about 1% of the supplement.
19. A stem cell line comprising a bovine embryonic stem cell (bESC), wherein the bESC maintains its pluripotency and self-renewal capacity.
Citation Information
Patent Citations
Generation and maintenance of stem cells
US20120028351A1
Media for culturing pluripotent stem cells
US20170275593A1
Efficient derivation of stable pluripotent bovine embryonic stem cells
US20200385674A1
Cited By
Application of tetracycline drug in synchronous separation and maintenance of bovine embryonic stem cells and bovine trophoblast stem cells
WO2026166135A1
